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Abstract 
ADAM12 (A Disintegrin and Metalloprotease 12) is a cell surface protease, which is 
deregulated in many human diseases. High expression of ADAM12 in triple-negative breast 
cancers (lacking estrogen receptor, progesterone receptor, and HER2 expression) is associated 
with poor patient prognosis. My dissertation focused on the understanding of the biological 
functions of ADAM12 in triple-negative breast cancers. I found that ADAM12 is significantly 
upregulated in the claudin-low molecular subtype of breast cancer. Claudin-low tumors are 
typically triple-negative and are enriched in cancer stem cells. Here, I demonstrated that the loss 
of ADAM12 expression not only decreased the number of cancer stem-like cells in vitro but also 
significantly compromised the tumor-initiating capabilities of breast cancer cells in vivo. This is 
the first evidence showing that ADAM12 might regulate the cancer stem cell-like phenotype in 
triple-negative breast cancers. I also discovered a novel mechanism of ADAM12-regulated 
signaling by transforming growth factor β (TGFβ) through modulation of TGFBR1 mRNA 
expression in breast cancer cells. Lastly, I characterized the effects of six different somatic 
mutations in the ADAM12 gene found in human breast cancers on the intracellular trafficking, 
post-translational processing, and function of ADAM12 protein. Collectively, the findings of this 
study support the notion that ADAM12 with catalytically active metalloprotease domain is 
required for the progression of triple-negative breast cancers. 
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Chapter 1 - Introduction 
 Metalloprotease ADAM12 in Breast Cancer 
 Overview of the ADAM metalloproteases 
A Disintegrin And Metalloprotease is a family of membrane-anchored proteases. 
ADAMs, together with snake venom metalloproteases (SVMPs) and ADAMs containing 
thrombospondin motifs (ADAMTs), are members of the M12B adamalysin peptidase subfamily 
(Jones et al., 2016).  So far, twenty-two human ADAM metalloprotease have been identified, 
twelve of which possess full protease activity (Jones et al., 2016). A typical ADAM protein 
possesses a signal sequence, a prodomain, a metalloprotease domain, a disintegrin domain, a 
cysteine-rich region, an EGF-like domain, a transmembrane domain, and a cytoplasmic domain 
(Figure 1.1A).  
The signal sequence of ADAMs are located at the N-terminus of the protein and lead the 
proteins into the secretory pathway (Edwards et al., 2008). Right next to the signal sequence is 
the prodomain of ADAMs, which not only behaves as a self-inhibitor to the metalloprotease site 
but also acts as an intramolecular chaperone to assure the correct folding of the protease 
molecule (Roghani et al., 1999). The prodomain of the ADAM metalloprotease is cleaved by 
furin-like enzymes in the Golgi or is auto-cleaved when passing through the secretory pathway 
(Howard et al., 2000; Schlomann et al., 2002) or later in the secretory pathway. 
Metalloprotease domain connects immediately to the C-terminus of the prodomain. The 
ADAM metalloproteases are endopeptidases containing His-Glu-Xaa-Xaa-His-Xaa-Xaa-Gly-
Xaa-Xaa-His motif, in which Xaa is hydrophobic or threonine (Jongeneel et al., 1989). The three 
histidine residues bind to a zinc atom and line up with glutamate residue forming the protease 
catalytic center (http://merops.sanger.ac.uk/cgi-bin/famsum?family=M12). In the catalytic site of 
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ADAMDEC1, the third  histidine residue is replaced by an aspartate residue (His-Glu-Leu-Gly-
His-Val-Leu-Gly-Met-Pro-Asp) (Bates et al., 2002).  
Eight human ADAMs are catalytically inactive: ADAM2, ADAM7, ADAM11, 
ADAM18, ADAM22, ADAM23, ADAM29, and ADAM32, suggesting ADAMs could function 
through direct protein-protein interaction mediated by other domains of the protein (Edwards et 
al., 2008). The disintegrin domains of ADAMs have been intensively studied due to their 
potential to interact with adhesion molecule integrins. Studies had proved that ADAMs 
interacted with specific integrins, such as α2β1, α4β1, α4β7, α5β1, α6β1, α6β4, α9β1, αVβ3, and 
αVβ5 and that these interactions played roles in cell adhesion and cell-cell interactions (Eto et 
al., 2002). 
The cysteine-rich domain is important for ADAMs substrate interactions. Gaultier’s 
group showed that the Cys-rich domain was required for ADAM13 binding to fibronectin and for 
ADAM17 mediated IL-1 receptor-II cleavage (Gaultier et al., 2002; Reddy et al., 2000). Besides, 
the unique structure formed by the Cys-rich domain and the disintegrin domain via disulfide 
bonds allowed the cysteine-enriched region facing directly towards the active center of the 
metalloprotease domain and facilitated the effective cleavage of the substrate (Takeda et al., 
2006; Janes et al., 2005). Since the Cys-rich region has a hyper-variable region (HVR), which is 
not conserved among different ADAM members, it has been proposed that the structural motif 
formed by the disintegrin and Cys-rich domain through disulfide bonds could be an essential 
module or substrate interaction site of ADAMs (Takeda et al., 2006; Zhang et al., 2015).  
The intracellular portions of ADAM proteins contain one or more proline-rich regions, 
which are potential interacting sites for Src Homology 3 (SH3) domain-containing proteins (such 
as Src, Yes, Grb, et al) (Ebsen et al., 2014), suggesting that ADAMs may function as signaling 
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molecules in a protease-independent manner. The C-terminal tails also regulate the intracellular 
trafficking of ADAM proteins. The cytoplasmic tail of ADAM10 harbors an arginine-rich 
region, mutation of which causes the retention of the protein in the endoplasmic reticulum and 
poor cell surface localization (Marcello et al., 2010). Interestingly, there is evidence showing 
that phosphorylation of the cytoplasmic domain is required for ADAM17 mediated ectodomain 
cleavage (Killock & Ivetić, 2010; Prakasam et al., 2014). 
ADAM proteins are glycosylated during the process of synthesis in the endoplastic 
reticulum and Golgi. Though the exact structure and the function of the sugar moieties still 
remain unclear, there is evidence showing that the accurate glycosylation is essential for the 
protein to acquire the full enzymatic activity. Srinivasan and his group showed that the N-
glycosylation on Asn91 and Asn612 of ADAM8 were critical for the maturation and surface 
localization of the protein (Srinivasan et al., 2014). ADAM8 with N91Q or N612Q mutations 
failed to pass beyond Golgi and endoplastic reticulum, respectively. 
 ADAM12 in breast cancer 
ADAM12 is highly upregulated in breast tumor and breast cancer cell lines (Lendeckel et 
al., 2005; Kveiborg et al., 2005; Li et al., 2012; Kveiborg et al., 2008; Li et al., 2013) and is also 
recognized as a candidate cancer gene in breast cancer (Sjӧblom et al., 2006). Studies have 
shown that ADAM12 is expressed in the intralobular area of breast tumors and the invading 
tumor cells (Kveiborg et al., 2005; Kveiborg et al., 2008). In triple-negative breast cancer, 
ADAM12 expression level was strongly associated with the activation of EGFR and shorter 
metastasis-free survival times (Li et al., 2012). Besides, ADAM12 was shown to be elevated in 
claudin-low subtype breast cancers and linked to tumor-initiating phenotype of cancer cells (Li et 
al., 2013) Thus, it is important to understand how ADAM12 is regulated in breast cancer. 
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 Regulation of ADAM12 expression  
Regulation of ADAM12 by TGFβ signaling 
Transforming growth factor (TGF) β signaling pathway has been shown to regulate the 
expression of ADAM12 at both the transcriptional and the translational level in breast cancer cell 
lines (Li et al., 2012; Ruff et al., 2015). TGFβ-mediated ADAM12 regulation was first reported 
by Le Pabic and coworkers in human hepatic stellate cells (HSCs), which are activated from the 
quiescent status by inflammatory or other liver damage stimuli (Le Pabic et al., 2003). Le Pabic 
and coworkers found that ADAM12 expression was significantly elevated by TGFβ treatment in 
human activated HSCs and in liver cancers (Le Pabic et al., 2003; Le Pabic et al., 2005). Long 
term treatment with MAPK inhibitor LY294002, PI3K inhibitor UO126, or mTOR inhibitor 
Rapamycin decreased the induction of ADAM12 mediated by TGFβ in HSCs, suggesting that 
TGFβ might modulate ADAM12 gene expression in Smad-independent manner through 
PI3K/mTOR and MEK/ERK pathways. Beside, TGFβ signaling also mediated the elevated 
ADAM12 expression triggered by NF-κB signaling (Ray et al., 2010). 
SnoN, a transcription suppressor of TGFβ signaling, has been shown to be a negative 
regulator of ADAM12 expression in mouse fibroblast cells (Solomon et al., 2010). Upon adding 
TGFβ, SnoN is targeted by Smad2/3 and Smurf-2 for proteasomal degradation (Deheuninck et 
al., 2009). The process is Smad-dependent and responds shortly after TGFβ treatment. 
Overexpression of SnoN partially but significantly decreased TGFβ mediated ADAM12 
induction, whereas down-regulation of SnoN by shRNA caused a robust increase of ADAM12 at 
both mRNA and protein levels (Solomon et al., 2010). 
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Regulation of ADAM12 by ErbB2 activation 
ErbB2 is a receptor tyrosine kinase and is also known as HER2. Studies have also shown 
that ErbB2 activation induced ADAM12 expression in human head and neck squamous 
carcinoma cells (HNSCCs) (Rao et al., 2012; Rao et al., 2014). Overexpression of ErbB2 
resulted in the up-regulation of ADAM12 via ErbB2/PI3K/Akt/mTOR signaling cascade. 
Conversely, up-regulated ADAM12 promoted the expression of ErbB2 through transcription 
factor Ets-1 in HNSCC cells (Rao et al., 2012). A positive activation loop was proposed between 
ADAM12 and ErbB2 expression, which might attribute to the tumor malignancy of UV-induced 
skin cancers and human head and neck cancers (Rao et al., 2012; Rao et al., 2014). However, no 
detailed molecular mechanism has been available to explain how mTOR regulates ADAM12 
expression and how ADAM12 modulates Ets-1 transcription activity. 
Post-transcriptional regulation of ADAM12 by microRNAs 
ADAM12-L and ADAM12-S are two ADAM12 isoforms: ADAM12-L represents the 
long, transmembrane isoform of ADAM12; whereas ADAM12-S has neither transmembrane 
domain nor cytoplasmic tail and is released from cells after being synthesized (Figure 1.1B). 
Studies showed that ADAM12-L, but not ADAM12-S, is not only strongly upregulated in the 
claudin-low molecular subtype of breast cancer but also of prognostic value (Li et al., 2013). 
Since ADAM12-L and -S are encoded by two alternative transcript variants of ADAM12 with 
differences at 3’-untranslated regions (3’UTRs), it was postulated that the 3’UTRs of ADAM12 
might be the target of post-transcriptional regulation. Our recent published data suggested that 
miR-200b/c and miR-29b/c directly target the 3’UTR of ADAM12-L and negatively regulate the 
expression of ADAM12-L (Duhachek-Muggy et al., 2015). 
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miR-200b/c are members of the miR-200 family, which has shown to be a negative 
regulator of breast cancer stem cell properties and an inducer of Epithelial-to-Mesenchymal 
Transition (EMT) (Schwarzenbacher et al., 2013). Down-regulation of the miR-200 family was 
often observed in breast cancer stem cells, normal mammary stem cells, and embryonal 
carcinoma cells (Shimono et al., 2009).  The miR-29 family, which consists of 3 isoforms, has 
been shown to be downregulated in various types of cancers, including invasive breast cancer 
(Iorio et al., 2005; Garzon et al., 2009). Studies showed that miR-29b is involved in the 
regulation of apoptosis and tumorigenic potential in leukemia, lung, and prostate cancer cells 
(Mott et al., 2007; Garzon et al., 2009; Ru et al., 2012). 
Our results showed that transfection of miR-29b/c mimics resulted in a significant down-
regulation of ADAM12-L in SUM159PT and BT549 breast cancer cell lines with no effect on 
ADAM12-S (Duhachek-Muggy et al., 2015). miR-200b/c mimics induced a dramatic decrease of 
ADAM12 translation in Hs578T cells and reduction of ADAM12-L at both mRNA and protein 
levels in SUM1315MO2. miR-29b/c and miR-200b/c mimics also inhibited the activity of 
ADAM12-L 3’UTR reporter. The inhibitory effects disappeared when the targeting sites of miR-
29b/c and miR200b/c were mutated. In all, this finding indicates that miR29-b/c and miR-200b/c 
directly target ADAM12-L 3’UTR and regulate its expression at post-transcriptional level. 
Regulation of ADAM12 expression by protein intracellular tranfficking 
ADAM12 activity can be regulated at the post-translational level by PKCε, c-Src, and 
clathrin. PKCε interacted with ADAM12 via regulatory domain and promoted the surface 
translocation of ADAM12 in a kinase-dependent manner (Sundberg et al., 2004). Though it has 
been shown that PKC activation stimulates the regulated protein secretory pathway (Traub & 
Kornfeld, 1997), through which ADAM12 translocates to cell surface, no detailed mechanism 
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model has been proposed which would explain how PKCε increases the surface translocation of 
ADAM12. Studies have also shown that proteins of the Src family regulate ADAM12 cellular 
localization (Stautz et al., 2010). Grb2 and c-Src bind to ADAM12 cytoplasmic tail at the 
cysteine-rich region and cause ADAM12 translocation from the near-nuclear area to peripheral 
punctate structures of the cell (Stautz et al., 2012; Stautz et al., 2010; Suzuki et al., 2000). 
Clathrin has been found to be involved in the regulation of ADAM12 endocytosis. Down-
regulation of clathrin decreased ADAM12 turnover rate and thus enhanced ADAM12 function at 
the cell surface (Ren et al., 2011). 
 Function of ADAM12 in breast cancer 
ADAM12 promotes breast cancer progression via EMT 
ADAM12 was shown to be actively involved in epithelial-to-mesenchymal transition 
(EMT) and thus to promote breast tumor progression and dissemination. EMT is a gene 
expression reprogramming process that could occur either in physiological or pathological 
contexts (Lamouille et al., 2014). In the context of cancer, EMT features downregulate adhesion 
molecule expression, enhance migration capability, and increase resistance to apoptosis (Kalluri 
& Weinberg, 2009). EMT is also closely associated with a subpopulation of cancer cells that 
possess stem cell-like phenotype and are capable of initiating tumors (Kalluri & Weinberg, 2009; 
Lamouille et al., 2014). Therefore, EMT promotes tumor progression and dissemination. TGFβ 
is a potent EMT inducer. Long-term treatment with TGFβ not only induces EMT but also leads 
to a strong upregulation of ADAM12 at both mRNA and protein levels (Atfi et al., 2007; 
Solomon et al., 2010; Li et al., 2013). On the other hand, ADAM12 was demonstrated to 
enhance TGFβ signaling by stabilizing TGFBR1 via interacting with TGFBR2, which would 
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form a tetramer complex with TGFBR1 upon binding with TGFβ (Atfi et al., 2007; Gruel et al., 
2009). 
Breast tumors and cell lines with mesenchymal characteristics show potent tumor 
initiating capability as well as abundant ADAM12 expression. A study of Li and coworkers 
further demonstrated that ADAM12 was significantly associated with breast tumor-initiating 
phenotype (Li et al., 2013). Recently published data revealed that overexpression of ADAM12 in 
MCF10A, a breast epithelial cell line, led not only to a dramatic cytoskeleton change but also 
elevated expression of EMT markers (Ruff et al., 2015), suggesting that ADAM12 could 
facilitate or even induce EMT in breast cells. Interestingly, this evident effect did not require the 
proteolytic activity of ADAM12 but was associated with the activation of ERK signaling 
pathway (Ruff et al., 2015).  
ADAM12 increases apoptotic resistance of breast cancer cells 
 In vivo studies have shown that ADAM12 might play an active role in breast tumor 
progression via decreasing the sensitivity of cancer cells to apoptosis (Kveiborg et al., 2005; Roy 
et al., 2011). Overexpressed ADAM12-Δcyt increased the apoptotic sensitivity of non-cancerous 
cells, whereas in breast tumor cells, the exogenous ADAM12 induced the opposite effect: 
ADAM12 significantly enhanced the apoptosis resistance of breast tumor cells and thus 
promoted tumor progression (Kveiborg et al., 2005). This in vivo study further demonstrated that 
both ADAM12-Δcyt/PyMT and ADAM12S/PyMT transgenic mice had low tumor free rates, 
increased total tumor mass, and elevated ADAM12 expression in malignant tumor samples. The 
protease activity of ADAM12 was not required for the acquisition of apoptosis resistance. 
In human breast cancer cells, ADAM12-mediated matrix metalloprotease-14 (MMP-14) 
activation promotes cancer cell survival as well as invasion. ADAM12 overexpression in breast 
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cancer cells induced MMP14 expression and therefore promoted the degradation of an 
extracellular matrix component gelatin (Albrechtsen et al., 2013). More importantly, ADAM12-
mediated MMP14 activation resulted in decreased expression of pro-apoptotic proteins 
BCL2L11 and BIK, leading to reduced apoptotic sensitivity of cancer cells (Albrechtsen et al., 
2013). Intriguingly, both effects required neither protease activity nor cytoplasmic tail of 
ADAM12, suggesting that ADAM12 may function through protein-protein interactions mediated 
via the extracellular domain. Orthotopic implantation of MCF7 cells with overexpressed 
ADAM12 further confirmed that ADAM12 facilitated tumor progression and reduced tumor 
apoptosis in vivo (Albrechtsen et al., 2013). 
ADAM12-mediated growth factor cleavage promotes breast cancer progression and 
metastasis 
ADAM12 sheddase activity is of great importance for breast tumor progression and 
metastasis. Sonic hedgehog, Delta-like1, HB-EGF, EGF, and β-cellulin are ADAM12 substrates, 
activating key signaling pathways that regulate cell proliferation, migration, and differentiation 
(Kveiborg et al., 2008; Ohlig et al., 2011; Frӧhlich et al., 2013). HB-EGF, EGF, and β-cellulin 
are ligands of EGF receptors, activating EGFR signaling pathway, which promotes the growth, 
migration, survival, and tumor initiation of breast cancer cells (Appert-Collin et al., 2015; Lo et 
al., 2006). VE-cadherin (vascular endothelial cadherin), Flk-1 (fetal liver kinase-1), and Tie-2 
(receptors of angiopoietin) are expressed in endothelial cells and are required for proper 
vasculature formation (Carmeliet et al., 1999; Maisonpierre et al., 1997). ADAM12 was 
demonstrated to be able to cleave these membrane-associated proteins, suggesting that ADAM12 
may promote breast tumor metastasis through affecting blood vessel structure or formation 
(Olsson et al., 2006; Fukuhara et al., 2008; Frӧhlich et al., 2013). Additionally, ADAM12 
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mediated VE-Cadherin shedding may potentially facilitate cancer cells invasion through blood 
vessel walls as VE-cadherin regulates vascular permeability (Corada et al., 2001; Frӧhlich et al., 
2013). 
A study of ADAM12 mutants showed that protease enzymatic activity of ADAM12 is 
important for cell motility. Cells with overexpressed wild-type ADAM12 migrated faster and 
showed higher phosphorylation of EGFR than cells with catalytically inactive mutants (Qi et al., 
2014). More importantly, ADAM12 mutants with impaired protease activity were not included in 
triple-negative breast cancer and the mutants that appeared in triple-negative breast cancer 
possessed full enzymatic activity. These results suggest that the protease activity of ADAM12 
might be critical for triple-negative cancer progression (Qi et al., 2014; Li et al., 2012). 
ADAM12 induces drug resistance in ERα-positive breast cancer cells 
ADAM12 was also shown to induce anti-estrogen resistance in MCF7 cells (Roy et al., 
2012). Estrogen receptor α (ERα) is a major estrogen receptor isoform, usually overexpressed in 
ER-positive breast cancer cells, and thereby is routinely used as a protein marker in breast cancer 
diagnosis (Badve & Nakshatri, 2009). Roy and coworkers observed that overexpression of 
ADAM12 in ERα-positive MCF7 cells promoted the growth of tumor cells in an estrogen-
independent manner (Roy et al., 2012). Also, the same study discovered that MCF7 cells with 
ADAM12 overexpression showed higher phosphorylation of EGFR, insulin-like growth factor-1 
receptor (IGF-1R), and MAPK, as well as increased amphiregulin cleavage, suggesting 
ADAM12-mediated EGFR, IGF-1R, and MAPK activation via amphiregulin cleavage might be 
the driving force of tumor growth (Roy et al., 2012). In all, a large number of previous studies 
suggest that ADAM12 is actively involved in the breast cancer progression, especially in triple-
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negative breast tumors, and that ADAM12 could serve as a potential target for breast cancer 
treatment.  
 
 Role of EGFR Signaling in Breast Cancer 
 Overview of EGFR signaling pathway 
The epidermal growth factor receptor (EGFR) signaling pathway is one of the major cell-
cell communication signaling pathways, which is of significant importance in cell fate 
determination, cell proliferation, cell migration and apoptosis (Yang & Baker, 2003; Yarden & 
Shilo, 2007). Owing to its critical biological functions, EGFR signaling has been extensively 
studied in the context of tumorigenesis, progression, and drug resistance.  
 Receptors and ligands  
Receptors 
Epidermal growth factor receptor (EGFR) is a transmembrane receptor tyrosine kinase 
whose activation requires the binding of EGF-like ligands. EGFR belongs to the family of four 
ErbB receptors, which consist of EGFR (also known as ErbB1), ErbB2 (also known as HER2), 
ErbB3, and ErbB4. Protein structures of the four receptors are similar (Figure 1.2), containing an 
extracellular ligand-binding domain, a single transmembrane region, and a conserved 
intracellular tyrosine kinase (TK) domain (Linggi & Carpenter, 2006). 
EGFR and ErbB4 require the binding of cognate ligands to form a homo- or heterodimer, 
which sequentially induces autophosphorylation of the TK domain and activates downstream 
signaling pathways. ErbB2 behaves as an orphan receptor and does not interact with any ligands 
(Ward et al., 2007). ErbB3 possesses no tyrosine kinase activity. Both of ErbB2 and ErbB3 are 
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capable of activating signaling pathways through heterodimerization with other ErbB receptors 
(Citri & Yarden, 2006).  
Ligands 
The ErbB receptors can be activated by eleven different ligands; epidermal growth factor 
(EGF), transforming growth factor-α (TGF-α), heparin-binding EGF (HB-EGF), β-cellulin 
(BTC), amphiregulin (AREG), epiregulin (EREG), epigen (EPGN), and neuregulin1-4 (NRG1-4, 
also known as heregulins) (Schneider & Yarden, 2014) (Figure 1.3). These ligands are small 
water-soluble protein molecules that share a highly conserved EGF-like motif (Tebbutt et al., 
2013). Each of the ligands is encoded by an individual gene, synthesized as membrane-anchored 
precursor, and cleaved by an ADAM protease (Zeng et al., 2014; Sahin et al., 2004). The 
involvement of ADAM 9, -10, -12, -15, -17, and -19 in the cleavage of EGFR ligands has been 
well documented in the literature (Blobel, 2005; Horiuchi et al., 2007; Le Gall et al., 2009). 
ErbB receptors interact selectively with their preferred ligands (Figure 1.2), with the 
exception of ErbB2, which does not bind any ligands (Linggi et al., 2006). Interestingly, though 
all the ligands are capable of triggering EGFR signaling, the outcomes are often different for 
different ligands. For example, both AREG and TGF-α are able to induce cell division and 
proliferation, but only AREG is capable of affecting the distribution of E-cadherin and changing 
the morphology of kidney cells (Berasain & Avila, 2014).  
Expression of EGFR ligands can be regulated at the transcriptional (promoter activity), 
post-transciptional (mRNA stability), and post-translational levels (sheddase availability and 
activity) (Berasain & Avila, 2014). Dysregulation of EGFR ligands usually leads to enhanced 
and extended activation of EGFR signaling and thus is commonly associated with various types 
of tumors (Taylor et al., 2014). 
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Downstream signaling cascades 
Activated EGFR recruits several effectors and sequentially turns on downstream 
pathways that regulate critical cellular events. Traditional EGFR signaling downstream pathways 
include: PLC-γ-CaMK/PKC, Ras/Raf/MAPK, PI3K/Akt/mTOR, and STATs (Han & Lo, 2012) 
(Figure 1.4). 
 Activation of PLC-γ-CaMK/PKC regulates the expression of pro-apoptotic proteins, 
such as procaspase-2, -7, -8, and promotes cell proliferation by phosphorylating cdc25c. As a 
result, PLC-γ-CaMK/PKC plays critical roles in the regulation of cell proliferation, cell death, 
cell-cell contacts, and secretion (Mochly-Rosen et al., 2012; Litosch, 2015). Mitogen-activated 
protein kinases (MAPKs) selectively phosphorylate proteins at Ser/Thr/Tyr amino acid residues 
and regulate cell proliferation, mitosis, cell survival and apoptosis (Pearson et al., 2001). 
PI3K/Akt/mTOR is one of the critical signaling pathways participating in multiple cellular 
processes, such as cell proliferation, cell cycle, and apoptosis (Lo et al., 2006). 
Signal transducer and activator of transcription (STAT) is a family of transcription 
factors that are actively involved in immune responses, proliferation, and differentiation 
(Aaronson & Horvath, 2002). Recent studies have shown that STAT3 can be either directly 
phosphorylated by EGFR/ErbB2 or through EGFR/JAK1/2, and that dysregulation of STAT3 is 
frequently associated with breast tumor initiation, angiogenesis, and metastasis (Brooks et al., 
2014). 
 EGFR signaling in breast cancer 
 EGFR signaling promotes breast cancer migration 
The capability to migrate is the prerequisite function for cancer cells to invade and 
metastasize (McLean et al., 2005). EGFR signaling alteration is related to advanced stages of 
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malignancy and metastatic potential of breast cancers (Sainsbury et al., 1988; Viale et al., 2009; 
Hohensee et al., 2013). Several mechanisms have been proposed to illustrate how EGFR 
signaling modulates cancer cell migration and invasion, for example, up-regulation of 
metalloprotease/collegenase expression in breast cancers (Zhou et al., 2014; Seoane et al., 2015; 
Kondapaka et al., 1997; Navarini et al., 2015), activation of focal adhesion kinase (FAK) 
phosphorylation (Sieg et al., 2000), or increase of c-Src activity (Marcotte et al., 2012).   
 EGFR signaling elicits cancer treatment resistance 
Increased EGFR signaling is associated with the therapy resistance of ERα+ breast cancer 
(Massarweh et al., 2008; Jin et al., 2012; Ciupek et al., 2015). Several reports indicate that 
tamoxifen-resistant ERα+ breast cancer cells frequently show upregulated EGFR/ErbB2 
expression and phosphorylation (Shou et al., 2004; Arpino et al., 2005; Jin et al., 2012; Ciupek 
et al., 2015). EGFR/RAS/MAPK and EGFR/PI3K/Akt downstream cascades have been shown 
to contribute to the chemoresistance in breast cancer cells, which promote breast cancer cell 
survival via inhibiting apoptosis (Tanabe et al., 2003; Shou et al., 2004; Polzien et al., 2011) and 
cell-cycle checkpoints (Wang et al., 2010; Chakrabarty et al., 2013; She et al., 2005). 
 EGFR signaling induces EMT  
Accumulating evidence shows that EGFR signaling promotes migration, metastasis, and 
chemoresistance via inducing EMT. EMT is a transcription reprogramming process that 
promotes cell transition from the epithelial to mesenchymal-like phenotype, which is 
characterized by E-cadherin down-regulation and the increase of vimentin (Peinado et al., 2007; 
Barr et al., 2008). EMT enables cancer cells to be more motile, to escape the primary tumor site, 
and generate metastatic lesions at distant sites (Barr et al., 2008). Hence, EMT plays an 
important role in tumor progression and metastasis. 
 15 
EGFR signaling down-regulates E-cadherin expression via decreasing Caveolin-1 level 
and increasing Snail promoter activity, which eventually leads to the induction of EMT (Lu et 
al., 2003). EGFR signaling also induces EMT through activation of Signal Transducer and 
Activator of Transcription 3 (STAT3). EGFR signaling has been denomstrated to stimulate the 
binding of activated STAT3 to the STAT3 elements region of TWIST promoter, leading to the 
up-regulation of TWIST expression and induction of epithelial-to-mesenchymal transition (Lo et 
al., 2007). 
 Regulation of breast cancer stem cell by EGFR signaling 
Cancer stem cells (CSCs) are a small population of cells characterized as slow cycling, 
less differentiated, and capable of self-renewal (Scheel et al., 2011). Accumulating evidence has 
shown that cancer stem cell population is accountable for the resistance to chemotherapy, tumor 
relapse, and metastases (Pinto et al., 2013; Park et al., 2014; Lee et al., 2011). EGFR/ErbB2-
mediated STAT3 phosphorylation plays a key role in the regulation of CSCs in breast cancer 
(Chung et al., 2014; Thakur et al., 2015; Chung et al., 2013; Wei et al., 2014).  
STAT3 pathway in breast CSC regulation 
STAT3 is a member of the STAT transcription factor family, which are downstream 
effectors responding to extracelluar cytokines and growth factors (Resemann et al., 2014). 
STAT3 regulates the transcription of genes (such as FOS, MYC, and MCL1) involved in 
inflammation, apoptosis, differentiation, stem cell maintenance, and transformation (Resemann 
et al., 2014; Lo et al., 2006). Activated EGFR regulates STAT3 phosphorylation directly or 
indirectly via JAK1/2, c-Src, or PI3K/Akt/mTOR (Lo et al., 2006; Silva, 2004; Zhou et al., 
2007). 
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STAT3 not only promotes the conversion of cancer cells from non-stem-like to stem-like 
cell but also provides the signal for the CSC self-renewal (Thakur et al., 2015; Hollmén et al., 
2015). Expression and activation of STAT3 is elevated in CD44+/CD24-/low and aldehyde 
dehydrogenase positive (ALDH+) breast cancer stem-like cells (Thakur et al., 2015; Chung et 
al., 2013; Lin et al., 2013). The similar effect was also observed in tumor-initiating cells in 
claudin-low breast cancers (Wei et al., 2014). Suppression of STAT3 activity or protein 
expression results in decreased breast cancer stem cell-like cell population in vitro and in vivo 
(An et al., 2015; Zhu et al., 2014; Thakur et al., 2015). PI3K/Akt/mTOR is one of the classical 
EGFR signaling downstream pathways (Lo et al., 2006), which has shown to be significantly 
activated by the STAT3 signaling pathway and therefore regulated in stem-like cell 
subpopulation in MCF7 breast cancer cells (Zhou et al., 2007). 
Macrophage regulates breast CSCs 
Emerging evidence unveils the involvement of tumor-associated macrophages (TAMs) in 
the maintenance of CSC subpopulation in breast tumors (Raggi et al., 2016). Studies have 
demonstrated that ER-negative breast cancer cells secrete colony stimulating factor 1 (CSF1) to 
educate EGF-secreting TAMs, which as a result prepare the microenvironment for tumor 
invasion (Goswami et al., 2005; Nickerson et al., 2013). Additionally, TAMs-EGFR-STAT3 
axis has been shown to promote breast cancer invasion and initiate cancer stem cell niche 
(Vlaicu et al., 2013).  The sphere formation capability of breast cancer cells is enhanced when 
cells are co-cultured with TAMs. Besides, the increased sphere formation is abolished when the 
co-cultured cells are incubated with macrophage-interfering reagents (Ward et al., 2015). 
Recently, another signaling cascade of EGFR/STAT3/Sox2 has been proposed by Yang and 
coworkers, through which murine breast tumors maintain their CSC population (Yang et al., 
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2013). Altogether, though a large number of studies have been already performed, more 
experiments are still needed to further determine whether and how the EGF paracrine loop 
between TAMs and breast tumor cells regulates CSC through STAT3 in human breast cancer. 
 
 Role of TGFβ receptors in the regulation of TGFβ signaling 
 Overview of the TGFβ signaling pathway 
Transforming growth factor β (TGFβ) signaling is a ubiquitous and multifunctional 
pathway, which controls a large variety of cellular and developmental processes. The TGFβ 
pathway has been demonstrated to be critical for the early embryonic development and to 
actively participate in the immune response and wound healing processes (Beyer et al., 2013; 
Finnson et al., 2013). Thus, it is not surprising that the dysregulation and malfunction of TGFβ 
signaling is associated with different diseases, such as inflammation, atherosclerosis, 
neurogeneration, and cancer progression (Gratchev et al., 2016; Damato et al., 2013; Katsuno et 
al., 2011; Pickup et al., 2013). 
 Ligands and receptors 
Ligands 
The TGFβ growth factor superfamily contains more than 30 members (Shi & Massagué, 
2003; Schmierer & Hill, 2007). According to the similarity of the protein sequences and 
downstream effector cascades, human TGFβ superfamily growth factors can be grouped into two 
categories: TGFβs/Activin/Nodal and BMP (bone morphogenetic proteins)/GDF (growth and 
differentiation factors)/MIS (Muellerian-inhibiting factors) (Figure 1.5) (Schmierer & Hill, 
2007). The TGFβ growth factor subfamily has three members: TGFβ1, TGFβ2, TGFβ3 (Shi & 
Massagué, 2003).  
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TGFβs are first synthesized as homodimeric pre-proproteins, containing a signal peptide, 
a pro-domain called latency-associated peptide (LAP), and a domain at C-terminus that becomes 
mature transforming growth factor-β after proteolytic processing (Khalil, 1999). When the 
protein is synthesized, the pro-domain is usually cleaved off but it still attaches to the mature 
TGFβ molecules noncovanlently (Dubois et al., 1995). After interacting with latent TGFβ-
binding protein (LTBP), the whole complex is secreted from the cell as a large latent complex 
(LLC) (Rifkin, 2005). Additional steps, such as metalloprotease-mediated cleavage and pH-
induced conformational changes, are required to fully activate the latent TGFβ complex and 
provide important regulatory mechanisms of TGFβ signaling (Ge & Greenspan, 2006; Wipff & 
Hinz, 2008). 
Receptors 
TGFβ receptors (TGFβRs) are transmembrane proteins that can be divided into two 
categories, type I and type II. In the human genome, type I TGFβ receptors have seven members 
(ALK1-7), whereas type II receptors are encoded by five genes (TGFBR2, ACTR2, ACTR2B, 
BMPR2, AMHR2) (Figure 1.5). An extracellular ligand binding domain, a transmembrane 
domain, and an intracellular Ser/Thr kinase domain are the main structural units of TGFβRs. The 
extracelluar domains of TGFβRs show diverse structural arrangements, which enable the 
receptors to interact with different ligands of the TGFβ superfamily (Schmierer & Hill, 2007).  
The Ser/Thr kinase domains of type II receptors are believed to be constantly active, and 
they phosphorylate the GS sequence of type I TGFβ receptors upon binding with their 
corresponding ligands. Type I receptors, on the other hand, contain a unique and highly 
conserved GS sequence (TTSGSGSG) at N-terminus of the kinase domain proximate to the 
transmembrane domain (Massagué, 1998). Phosphorylation of the GS sequence induces a 
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conformational change of the cytoplasmic tail and therefore increases the selectivity of the 
kinase domain for the C-terminus of Smad2 (Shi & Massagué, 2003). Activation of TGFβRs 
follows a certain order. Depending on the ligands, some factors of the TGFβ family (such as 
TGFβs) bind to the homodimer of type II TGFβR first, then the complex interacts with the type I 
TGFβR to form a tetramer that activates the signaling pathway. Other TGFβ family ligands, 
BMPs for example, interact with the type I TGFβR dimer first and then with type II receptors 
(Schmierer & Hill, 2007). 
 Smad-dependent and Smad-independent downstream cascades 
Smads are the main components of the canonical TGFβ signaling pathway and are 
classified into three types according to their functions: the receptor-regulated Smads (R-Smads), 
the common-mediator Smad (Co-Smad), and the inhibitory Smads (I-Smads) (Figure 1.5-1.6). R-
Smads have five members, Smad1, -2, -3, -5, and -8. Smad2 and Smad3 specifically transduce 
signal from TGFβs/activin/nodal, whereas Smad1, Smad5, and Smad8 prefer signaling from 
BMPs/GDFs (Schmierer & Hill, 2007). R-Smads contain Mad-homology (MH) 1 and MH2 
domains, which are responsible for DNA and receptors binding, respectively (Massagué, 2012). 
Upon the formation of TGFβR tetramer, the activated type I TGFβ receptors phosphorylate R-
Smads at the two serine residues at the C-terminus of R-Smads (Figure 1.6-1.7). Subsequently, 
the phosphorylated R-Smads complexes interact with the co-Smad protein Smad4, translocate 
into the nucleus, and then modulate the transcription of target genes (Miyazono et al., 2000; Shi 
& Massagué, 2003). The activity of TGFβ signaling can be negatively regulated by I-Smads, 
Smad6 and Smad7.  I-Smads are induced by TGFβ ligands in a R-Smad-dependent manner and 
are able to terminate TGFβ signaling through promoting the degradation of TGFβRs via 
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Smurf1/2 (Smad specific E3 ubiquitin protein ligase) or through eliciting TGFβRs 
dephosphorylation by phosphatase 1 (Miyazono et al., 2003; Massagué, 2000). 
The TGFβ superfamily also activates downstream cascades through non-Smad-mediated 
phosphorylation or protein-protein interactions, such as MAP kinase (MAPK) pathways, Rho-
like GTPase signaling pathways, PI3K/AKT pathways, and TGFβ activated kinase (TAK) 
1/TNFR-associated factor (TRAF) 6 pathways. These Smad-independent pathways and their 
underlying biochemical mechanisms have been extensively reviewed (Derynck & Zhang, 2003; 
Zhang, 2009; Choi et al., 2012) (Figure 1.7). These non-Smads dependent pathways allow TGFβ 
signaling participation in the regulation of various cellular and biological processes, such as cell 
proliferation, differentiation, cell fate determination, apoptosis, and cancer development (Zhang, 
2009). 
 Functions of the TGFβ signaling pathway 
The TGFβ superfamily is a pleiotropic cytokine family, which actively participates in 
various physiological and pathological processes, such as early embryonic and neuron 
development, cell survival, cell fate determination and differentiation, wound healing, immune 
responses, and cancer progression. The role of TGFβ in cancer is unique and context-dependent 
(Massagué, 2012; Akhurst & Padgett, 2015). In normal epithelial cells and early stages of 
cancers, TGFβ signaling functions as a tumor suppressor, which significantly decreases the 
proliferation rate of cells. Moreover, loss of TGFβ signaling causes tumor growth at early stages 
of tumor progression (Massagué, 2012; Harradine & Akhurst, 2006). On the contrary, TGFβ 
signaling, due to its potent role in the induction of epithelial-to-mesenchymal transition (EMT) 
(Xu et al., 2009), promotes cancer progression, angiogenesis, and malignancy at late stage 
(Gomes et al., 2012; Bierie et al., 2009; Janda et al., 2002). Many reports have shown that TGFβ 
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signaling is associated with poor prognosis, high risk of metastasis, and poor therapy response in 
different types of cancers (Elliott & Blobe, 2005; Biswas et al., 2006; Bhola et al., 2013; Li et 
al., 2013). Moreover, TGFβ also promotes tumor progression by preparing the 
microenvironment for tumor growth and dissemination, such as promoting the proliferation of 
cancer-associated fibroblasts by TGFβ-induced tissue connect growth factor (TCGF) secretion 
(Pickup et al., 2013; Papageorgis & Stylianopoulos, 2015).  
 Regulation of TGFβ signaling through TGFβ receptors 
Regulation of the availability of TGFβ receptors at the cell surface is one of the 
regulatory mechanisms controlling the activation of TGFβ signaling pathway. Studies have 
shown that TGFβR levels direct the specificity of the activation and biological functions of 
TGFβ signaling (Rojas et al., 2009).  
The regulation of type II TGFβ receptors (TGFβR2) has been well explored due to the 
fact that these receptors are constitutively active and are required for the activation of type I 
TGFβ receptors (TGFβR1). Studies have shown that the EGF/PI3K/Akt signaling cascade 
positively regulates the mRNA and protein levels of TGFBR2 in human dermal fibroblasts, 
which may contribute to the collagen overexpression in systemic sclerosis (Yamane et al., 2002; 
Yamane et al., 2003). At the post-transcriptional level, TGFBR2 mRNA expression is regulated 
by miR-337 and miR-153 via targeting the 3’-UTR of the TGFBR2 gene (Liang et al., 2015; 
Zhong et al., 2012). Endocytosis plays an important role in regulating the activity of TGFβ 
signaling. Depending on the type of the endocytic vehicles, TGFβ receptor internalization can 
either enhance or attenuate TGFβ signaling (Figure 1.8). Clathrin-mediated receptor trafficking 
promotes TGFβ signaling, while caveolin 1-induced endocytosis leads to the inhibition of TGFβ 
signaling (Di Guglielmo et al., 2003). Studies further revealed that clathrin-mediated early 
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endosomes are enriched in a protein called Smad Anchor for Receptor Activation (SARA), 
which recruits Smad2 and facilitates the binding of TGFβR1 and Smad2 (Hayes et al., 2002; Di 
Guglielmo et al., 2003). As a result, the activated TGFβ receptor complexes in these endosomes 
are still able to transduce the signal to the downstream pathways. Endocytic vehicles formed 
through lipid raft-caveolar pathway, on the other hand, contain high levels of Smad7 and 
Smurf2, which lead to the ubiquitination of TGFβ receptors and targeting for the lysosomal 
degradation, and eventually the termination of TGFβ signaling. In addition, ADAM12 has been 
shown to increase TGFβR2 in early endosomes and to enhance the stability of TGFβR2 by 
preventing the receptor from interactions with Smad7 (Atfi et al., 2007). However, this study 
was conducted in ADAM12 overexpression cell models, which are not convincing systems to 
illustrate the effect of ADAM12 on TGFβ receptors at the endogenous expression level. Thus, 
ADAM12 knockdown experiments by siRNAs or other methods are required to further confirm 
the observation that ADAM12 promotes the accumulation of TGFβR2 in endosomes. 
TGFβR1 (also known as activin-like kinase 5, ALK5) is a type I TGFβ receptor, 
phosphorylating R-Smads upon being activated by TGFβR2. Though TGFβR1 is the essential 
step to activate Smad-dependent signaling pathway, there is very limited knowledge on the 
regulation of TGFβR1. Similarly to TGFβR2, the TGFβR1 levels at the cell surface can be 
regulated by endocytosis (He et al., 2015; Di Guglielmo et al., 2003). Besides, Beclin1, an 
autophagy and protein trafficking regulatory protein, has been recently reported to facilitate the 
recycling of TGFβR1 to the cell surface and therefore enhance the TGFβ signaling in neuronal 
cells (O’Brien et al., 2015). Regarding the stability of TGFβR1, salt-inducible kinase (SIK) 1 
was shown to promote the degradation of TGFβR1 via interactions with Smad7 in a Smad-
dependent manner (Kowanetz et al., 2008). In addition, Notch signaling has been shown to up-
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regulate the mRNA expression of TGFβR1 through inhibition of neuropilin-1 (Nrp1), a 
membrane receptor interacting VEGF and other factors (Aspalter et al., 2015).  
 
 Goals of the Study 
In this study, my focus was to better understand the biological role of ADAM12 in breast cancer 
cells. 
• Our previous studies showed that the expression of ADAM12 was significantly up-
regulated in breast cancers of the claudin-low molecular subtype and was associated with 
decreased metastasis-free survival rates in triple-negative breast cancer. Claudin-low 
tumors are typically triple-negative and are enriched in cancer stem cells (Prat et al., 
2011). Thus, my goal was to determine whether and how ADAM12 contributes to the 
cancer stem cell-like features in triple-negative breast cancer cells.  
• ADAM12 was shown to enhance TGFβ signaling through interacting with TGFβR2 (Atfi 
et al., 2007) in ADAM12 overexpression cell models. Little effort has been put on 
illustrating the effect of ADAM12 on TGFβ signaling at the endogenous expression level 
in breast cancer cells. My goal was to investigate the role of ADAM12 in the regulation 
of TGFβ signaling in breast cancer cells using inducible shRNA knockdown system. 
• In human breast cancer, the ADAM12 gene is more frequently mutated than other ADAM 
genes that encode catalytically active ADAM proteases. Six different somatic missense 
mutations had been identified in human breast cancers. My goal was to explore the 
effects of these mutations on the structure, proteolytic processing, trafficking, and 
biological function of ADAM12. 
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Figure 1.1 Domain organization of ADAM metalloproteases and human ADAM12. 
 (A) A diagram showing the domain organization of the ADAM proteases. The 
metalloprotease activity requires the removal of the prodomain. The scissors indicate the 
cleavage of the prodmain of ADAM proteases. (B) The schematic diamgrams representing the 
domain structures of ADAM12-L and ADAM12-S, two major splice variants of human 
ADAM12. S, signal peptide; PD, prodomain; MP, metalloproteinase domain; D, disintegrin 
domain; CR, cysteine-rich domain; E, EGF-like domain; T, transmembrane region; CT, 
cytoplasmic tail; C, C-terminus. 
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Figure 1.2 Functional and structural features of ErbB receptor family.  
Adapted from Yarden et al., 2012 with permission from Nature Publishing Group. 
ErbB family receptors are transmembrane receptor tyrosine kinases. The black arrows are 
pointing to the ligand-binding site of each receptor. The binding of the ligands to the receptors 
induces the conformation change of the extracellular domain and exposes the interaction loop 
(labeled in dashed circles) for dimerization. ErbB2 can dimerize with no ligand binding because 
of its unique extracellular protein structure. The ATP-binding clefts are labeled by white arrows. 
ErbB3 has limited kinase activity. The corresponding ligands of each receptors are provided in 
the rectangular frames underneath each protein structure. 
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Figure 1.3 Ligands of ErbB family receptors.  
Based on Figure1 of Mei et al., 2008 & Harris et al., 2002 with permission from Nature 
Publishing Group and Elsevier Ltd. 
Ligands of ErbB family receptors are synthesized as transmembrane procursors and 
cleaved by membrane proteases, such as tumor necrosis factor-α converting enzyme (TACE, also 
known as ADAM17). The cleavage sites are marked by the yellow lightning symbols in the 
figure. All the ligands contain EGF-like domain and different N-terminal sequences. 
 
EGF, epidermal growth factor; TGF-α, transforming growth factor-α; AR, amphiregulin; HB-
EGF, haprin-binding EGF-like growth factor; BTC, β-cellulin; EPR, epiregulin, EPGN, epigen; 
NRG, neuregulin. 
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Figure 1.4 A diagram of EGFR downstream signaling pathways.  
Adapted from Nyati et al., 2006 with permission from Nature Publishing Group. 
Main downstream signaling cascades regulated by EGFR are summarized in the figure. 
Some key negative regulators, such as PTEN and MKP1, are also included. 
 
JAK, Janus kinase; STAT, signal transducer and activator of transcription; PI3K, 
phosphatidylinositol 3-kinase; PTEN, phosphatase and tensin homologue; MEK, mitogen-
activated protein kinase kinase; ERK, extracellular signal-regulated kinase, PLC, phospholipase 
c; DAG, diacylglycerol; PKC, protein kinase C; VEGF, vascular endothelial growth factor; 
ELK1, ETS domain-containing protein Elk-1; CCND1, gene name of protein cyclin D1; 
CDKN1A, gene encoding p21. 
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Figure 1.5 Ligands, receptors, and Smads of the TGFβ signaling pathway. 
Adapted from Schmierer et al., 2007 with permission from Nature Publishing Group. 
TGFβ super family growth factors, TGFβ receptors, and Smads proteins are grouped 
based on their protein sequences. Human proteins are labeled in black, where as D. melanogaster 
proteins are shown in grey. Alternative names of the proteins are included in parentheses. 
 
ACVR, activin receptor; ALK, activin receptor-like kinase; AMH, Muellerian-inhibiting factor; 
AMHR2, anti-Muellerian hormone type-2 receptor; BMP, bone morphogenetic protein 4; 
BMPR, BMP receptor; GDF, growth/differentiation factor; Co-SMAD, common-mediator Smad; 
I-SMAD, inhibitory Smad; R-SMAD, receptor-regulated Smad; TGF, ransforming growth 
factor; TGFBR, TGFβ receptor. 
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Figure 1.6 A brief review of Smad-dependent TGFβ downstream cascade. 
Adapted from Massagué et al., 2000 with permission from Nature Publishing Group. 
The binding of TGFβ ligands to pre-formed TGFβR homodimers leads to the formation 
of TGFβR tetramer and the phosphorylation of type I TGFβR homodimer. The activated type I 
TGFβ receptors phosphorylate R-Smads, which interact with co-Smad protein, translocate into 
the nucleus, and thus modulate the transcription of target genes (Miyazono et al., 2000; Shi et 
al., 2003). The R-Smads/co-Smad complex can be targeted either for degradation or recycling 
back to the cell surface. The degradation requires ubiquitination mediated by I-Smads and E3 
ubiquitin-protein ligase SMURFs. SARA is the scaffold protein that recruits R-Smads to TGFβ 
receptors (Massagué et al., 2000). 
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Figure 1.7 A diagram of Smad-independent TGFβ downstream pathways. 
Based on Figure 6 from Derynck et al., 2003 with permission from Nature Publishing Group. 
TGFβ signaling activates several other signal proteins and their downstream pathways 
(on the left in green) that do not require involvement of Smads. TGFβ-mediated TAK1 activation 
induces autophagy and thus plays important roles in the regulation of cell apoptosis and survival 
(Choi et al., 2012; Kang et al., 2011). 
 
TAK, TGFβ-activated kinase; AMPK, AMP-activated protein kinase; mTOR, mammalian target 
of rapamycin; NF-κB, nuclear factor-κB; MKK, dual specificity mitogen-activated protein kinase 
kinase; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; Erk, 
extracelluar signal-regulated kinase; ROCK, Rho-associated protein kinase; PP2A, protein 
phosphatase 2A; S6K, ribosomal protein S6 kinase 
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Figure 1.8 Regulation of TGFβ signaling via different TGFβR endocytic pathways. 
Based on Figure 7 from Di Guglielmo et al., 2003 with permission from Nature Publishing 
Group. 
TGFβ receptors can internalize through two different pathways. Clathrin-mediated 
endocytosis enhances TGFβ signaling (on the left in green), whereas the lipid raft-caveolar 
pathway (on the right in red) inhibits the transduction of TGFβ signals.  
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Chapter 2 - ADAM12 is a novel regulator of stem-like cells in triple-
negative breast cancer 
 
 Abstract 
Elevated expression of ADAM12 is a prognostic factor of metastasis in triple-negative 
breast cancers (TNBC) and a predictor of chemoresistance. ADAM12 is up-regulated in claudin-
low tumors enriched in cancer stem cell (CSC) markers. Here, we demonstrate that ADAM12 
regulates stem-like properties of SUM159PT and Hs578T TNBC cells. We found that ADAM12 
knockdown reduced cell migration and invasion, decreased anoikis resistance, and compromised 
mammosphere formation. ADAM12 knockdown also decreased the CD44+/CD24-/low and 
ALDEFLUOR+ cell populations and reduced tumorigenesis in mice in vivo. RNA sequencing 
identified a significant overlap between ADAM12- and EGFR-regulated genes. Erlotinib, an 
EGFR inhibitor, mimicked the effect of ADAM12 knockdown, and exogenous EGF blocked the 
effect of ADAM12 knockdown on CD44+/CD24-/low populations. These results indicate that 
ADAM12 supports the CSC phenotype in TNBC cells via modulation of the EGFR pathway. 
 
 Introduction 
 Members of the ADAM family of cell surface metalloproteases catalyze cell context-
dependent cleavage within the extracellular domains of transmembrane receptors, growth factor 
precursors, or adhesion molecules (Jones et al., 2015; Edwards et al., 2008). ADAM substrates 
include Notch receptors (Groot et al., 2014; van Tetering et al., 2009), Epidermal Growth Factor 
Receptor (EGFR) ligands (Blobel, 2005; Kataoka, 2009), interleukin-6 receptor (IL-6R) 
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(Schaper & Pose-John, 2015), transforming growth factor-α (TNF-α) (Li et al., 2015; Maney et 
al., 2015), E-cadherin (Maretzky et al., 2005; David et al., 2012), or CD44 (De Falco et al., 
2012; Hartmann et al., 2015). Because ADAMs are often aberrantly expressed or misregulated in 
human cancers, they may contribute to tumor progression, metastasis, or therapy resistance 
(Murphy, 2008; Duffy et al., 2009). 
 Among the twelve catalytically active human ADAMs (Jones et al., 2015; Edwards et al., 
2008), ADAM12 possesses unique characteristics that make it an attractive candidate for future 
targeting in breast cancer. ADAM12 expression is strongly elevated in human breast cancers 
compared to normal mammary epithelium (Bertucci et al., 2006; Kveiborg et al., 2005; 
Lendeckel et al., 2005). High levels of ADAM12 mRNA are associated with poor prognosis and 
decreased metastasis-free survival times in estrogen receptor (ER)-negative, progesterone 
receptor (PR)-negative, and epidermal growth factor receptor 2 (HER2)-negative (triple-
negative, TN) breast cancers, but not in HER2-positive or ER-positive tumors (Wang et al., 
2005; Li et al., 2012). ADAM12 expression is induced during epithelial-mesenchymal transition 
(EMT) in mammary epithelial cells, which is consistent with ADAM12 up-regulation in the 
claudin-low molecular subtype of breast cancer showing the molecular signatures of EMT 
(Taube et al., 2010; Li et al., 2013). Claudin-low tumors, which represent 5-10% of all breast 
cancers, are typically triple-negative, poorly differentiated, and have an augmented activity of 
EGFR, SRC, TGFβ and STAT3 pathways (Sabatier et al., 2014; Prat et al., 2010). Importantly, 
the gene expression signatures of claudin-low tumors show a significant similarity to the 
signature of CD44+/CD24-/low mammosphere-forming cells ( Sabatier et al., 2014; Creighton et 
al., 2009), suggesting an enrichment in cancer stem cell (CSC) or tumor-initiating cell (TIC) 
features. Breast CSCs are thought to be largely responsible for tumor maintenance, treatment 
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resistance, and disease recurrence (Baccelli, 2012; Nagaprashantha et al., 2011; Medema, 2013). 
Our previous analysis of two clinical datasets showed that elevated expression of ADAM12 is 
predictive of resistance to neoadjuvant chemotherapy in ER-negative breast cancer, independent 
of age, tumor size, grade, and the lymph node status (Li et al., 2013). These observations raised a 
possibility that ADAM12 may serve as a marker or a therapeutic target in breast CSCs in TN 
breast cancer. 
 The goal of the current study was to assess a possible contribution of ADAM12 to the 
CSC properties of TN breast cancer cells. By analyzing the effect of ADAM12 knockdown on 
cell migration, invasion, anoikis resistance, mammosphere formation, the known CSC markers, 
tumor formation after xenotransplantation in mice in vivo, and global gene expression, we have 
determined that ADAM12 actively supports the CSC phenotype of TN breast cancer cells. This 
function of ADAM12 appears to be mediated by modulation of EGFR signaling. Thus, we 
identify ADAM12 as a novel modifier of the EGFR pathway in TN breast cancer and a potential 
target in CSC-directed therapies.  
 
 Materials and Methods 
Reagents and antibodies 
ADAM12 siRNA smartpool, ADAM12 siRNA#1 (D-005118-01), ADAM12 siRNA#2 
(D-005118-02), control siRNA smartpool #1, control siRNA#3 (D-001206-13), and 
DharmaFECT1 transfection reagent were obtained from GE Dharmacon. RT2 Profiler arrays 
were purchased from QIAGEN.  Methylcellulose stock solution and growth factor-reduced 
Matrigel were purchased from R&D Systems and Corning, respectively. ALDEFLUOR kit was 
obtained from STEMCELL. Apoptosis was measured by Cell Death Detection ELISA kit from 
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Roche. Erlotinib was obtained from Cell signaling Technology. Vybrant DiO cell-labeling 
solution, bFGF, B27, and humam recombinant EGF were purchased from Life Technologies. 
Doxycycline and heparin was obtained from Sigma-Aldrich. Anti-Human ADAM12 mouse 
monoclonal antibody (#632525) and anti-mouse IgG1 isotype antibody (#11711) were purchase 
from R&D systems. APC-labeled goat anti-mouse IgG1 antibody was from Jackson 
ImmunoResearch. PE-conjugated mouse anti-human CD24 antibody (#ML5) and PE-conjugated 
mouse IgG2aκ isotype control antibody (G155-178) were obtained from BD Pharmingen. APC-
conjugated anti-human CD44 antibody (#IM7) and APC-conjugated IgG2bκ isotype control 
antibody (#eB149/10H5) were purchased form Affymetrix eBioscience. 
Cell culture 
SUM149PT, SUM159PT, and SUM1315MO2 cell lines were obtained from Asterand 
(Detroit, MI). BT549 and Hs578T cells were purchase from American Type Culture Collection 
(Manassas, VA).  HEK293T were obtained from Thermo Scientific. SUM102PT and 
SUM225CWN cells were a gift from Dr. Fariba Behbod (University of Kansas Medical Center). 
MCF-7 cell line was a gift from Dr. Annelise Nguyen (Kansas State University). SUM149, 
SUM159PT, and SUM225CWN cells were cultured in Ham’s F-12 medium supplemented with 
5% fetal bovine serum (FBS), 10 mM HEPES, 5 µg/ml insulin, and 1 µg/ml hydrocortisone. 
SUM1315MO2 cells were cultured in Ham’s F-12 medium supplemented with 5% FBS, 10 mM 
HEPES, 10 ng/ml epidermal growth factor (EGF), and 5 µg/ml insulin.  SUM102PT cells were 
maintained in Ham’s F-12 medium containing 5% FBS, 1 µg/ml hydrocortisone, 5 µg/ml insulin, 
and 1% Penicillin-Streptomycin-Amphotericin B (PSA). BT549 cells were cultured in 
RMPI1640 medium supplemented with 10% FBS, 1 mM pyruvate, and 0.8 µg/ml insulin. 
Hs578T and MCF-7cells were cultured in DMEM medium containing 10% FBS and 10 µg/ml 
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insulin. HEK293T cells were cultured in DMEM medium containing 10%FBS, 6 mM 
Glutamine, 1% Penicillin/ Streptomycin, and 110 µg/ml sodium pyruvate. Cells were maintained 
at 37° C under humidified atmosphere containing 5% CO2. 
Vectors/virus production and generation of stable cell lines 
shRNA targeting human ADAM12 and control shRNA sequences were excised from 
GIPZ ADAM12 shRNA (V2LHS_11814) or non-silencing lentiviral shRNA control 
(Cat#RHS4346; Thermo Scientific) and were cloned into pINDUCER10 vector (Addgene) at the 
XhoI and MluI sites. Lentiviruses were produced by transfecting HEK293T cells with 
pINDUCER10-shADAM12/shControl, pMD2.G, and psPAX2 plasmids (Addgene) using Mirus 
TransIT transfection reagent (Mirus).  Conditioned medium containing viral partiles was 
harvested 48h after transfection. SUM159PT cells were plated one day before infection at ~20% 
confluence. Conditioned medium containing viruses was supplemented with 5 ng/mL polybrene 
(Sigma) and was added onto SUM159PT cells. Selection of stably transduced cells started 48 
hours after infection using 2 µg/ml puromycin and continued for 10 days. 
Transwell migration assay 
SUM159PT shADAM12 and shControl cells were treated without or with 1 µg/ml 
Doxycycline for four continuous days. On the 4th day, cells were detached with 0.25% 
trypsin/1mM EDTA in DPBS, counted by Cellometer TM AutoT4 (Nexcelom Bioscience), and 
diluted to 2.5x104 cells/ml. Cells (500µl) were then added to the upper chambers of Transwell 
inserts. The inserts were placed into lower chambers filled with 700 µl of growth medium and 
incubated at 37°C for18 hours.  After washing the inserts twice with 500 µl DPBS, cells were 
fixed with 3% glutaraldehyde at room temperature for 20 minutes and stained with 0.5% crystal 
violet in 20% methanol for 15 minutes. Cells that did not migrate through the pores were 
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removed using cotton swabs. Migrated cells underneath the inserts were analyzed by light 
microscopy using 10x magnification and photographed. Numbers of migrated cells in 5 
randomly selected areas were counted manually. 
Sphere formation assay in methlycellulose 
SUM159PT shADAM12 and shControl cells were treated without or with 1 µg/ml 
Doxycycline for 4 days. Cells were detached with 0.25% trypsin/1mM EDTA in DPBS and 
counted by Cellometer TM AutoT4 (Nexcelom Bioscience). Single cell suspension at 1x106 
cells/ml were passed through cell strainer and then diluted to 5x103 cells/ml with mammosphere 
media containing MEMB (Lonza), 20 ng/ml hEGF (Life Technologies), 20 ng/ml bFGF (Life 
Technologies), 4 µg/ml heparin (Sigma), 1xB27 (Life Technologies), and 1x 
Penicillin/Streptomycin (Lonza).  Cell numbers among different treatments were adjusted within 
5% accuracy using CellTiter Glo kit (Promega) according to manufacturer’s instruction.  Cell 
suspension at the final dilution (5x103 cells/ml) was mixed with 3% methylcellulose (R&D 
Systems) at a ratio of 1:2. The solution was thoroughly mixed by vortexing and incubated at 
room temperature for 10 min. Cell suspension (500µl 103 cells in 1% Methylcellulose) was 
seeded into one well of 24-well ultra-low attachment plate (Corning). After 7 days, six randomly 
selected areas from each well were analyzed by light microscopy using a 4x objective and 
photographed. Numbers of spheres in each image were quantified using ImageJ. 
Measurement of cell death 
SUM159PT shADAM12 and shControl cells were treated without or with 1 µg/ml 
doxycycline for 4 days. One thousand suspended cells in 1% methylcellulose were seeded into 
each well of a 24-well ultra-low attachment plate (Corning), as in the sphere formation assay. 
Cells were collected at 0, 12, 24, and 48 hours post plating. Each sample was pelleted, washed 
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twice, lyzed at 4°C for 15 min, and frozen at -20°C. When the lysates of all samples were 
collected, the Cell Death ELISA kit (Roche) was used to detect the fragmented mono- and oligo-
nucleosomes in the lysate. The procedures and analysis were performed according to the 
manufacturer’s instruction. 
Flow cytometry   
SUM159PT cell and Hs578T cells were transfected with ADAM12 siRNA smart pool or 
non-targeting siRNA pool (Dharmacon). ALDEFLUOR assay: 5 days after transfection, cells 
were harvested, re-suspended at the density of 106/ml in the ALDEFLUOR assay buffer, 
followed by the addition of 5µl of the ALDEFLUOR Reagent to 1 ml of cell suspension. One 
half the cells (0.5 ml) were then transferred immediately to a new tube, which contained 10µl of 
ALDH inhibitor diethylamino-benzaldehyde (DEAB) serving as the negative control for the 
assay. The other half of cells was incubated without DEAB. Both tubes without and with DEAB 
were incubated at 37° for 45min. Then, cells were immediately transferred onto ice, centrifuged 
at 1200 rpm for 5 min at 4°C, and analyzed by flow cytometry using BD Calibur cytometer. 
CD24/CD44 assay: 5 days after transfection, cells were collected in 3% BSA/1xDPBS with 
calcium and magnesium, and then incubated for 30 minutes on ice with PE-conjugated anti-
CD24 antibody and APC-conjugated anti-CD44 antibody. Cells wre analyzed by flow cytometry 
BD Calibur cytometer. Erlotinib effect: SUM159PT cells were treated with 1 µM of Erlotinib in 
DMSO for 3 days. Cells were harvested and stained with anti-CD24 and anti-CD44 antibodies as 
described above. Efect of hEGF on CD24/CD44:  SUM159PT cells were transfected with 
ADAM12 siRNA #1 (D-005118-01), #2 (D-005118-02), or non-targeting siRNA #3 (D-001210-
10-05; Dharmacon) according to the manufacturer’s protocol. One set of the transfected cells 
was treated with 20 ng/ml hEGF. hEGF was added at the moment of transfection. The other set 
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of cells was incubated with no hEGF. Cells were collected and stained with anti-CD24 and anti-
CD44 antibodies, as described above for flow cytometry.  
 
 Results 
High ADAM12 expression in claudin-low subtype human breast tumor and breast 
tumor cell lines 
To explore the potential function of ADAM12 in breast cancer, we first examined the 
expression levels of ADAM12 in different molecular subtypes of breast tumors from the human 
tumor database of Netherlands Cancer Institute (NKI). As shown in Figure 2.1A, ADAM12 
mRNA is significantly elevated in the claudin-low subtype breast cancer compared to basal-like, 
HER2-overexpressing, and Luminal A and B subtypes. A significant increase of ADAM12 
expression in claudin-low subtype breast tumors was also observed from the analysis among the 
data retrieved from The Cancer Genome Atlas (TCGA) (Figure 2.1B).  More importantly, the 
claudin-low subtype breast tumor was shown to have tumor-initiating or stem cell phenotype and 
features of epithelial-mesenchymal transition (EMT) (Perou CM, 2010). 
We further examined ADAM12 protein levels in several breast cancer cell lines. Hs578T, 
SUM1315MO2, BT549, and SUM159PT cell lines were previously categorized as claudin-low 
using two different microarray platforms (Prat et al., 2013; Neve et al., 2006; Chin et al., 2006), 
SUM102PT and SUM149PT were classified as basal-like cell lines, and MCF-7 and 
SUM225CWN cell lines represent the luminal subtype. Consistent with the results of data 
mining, our flow cytometry analysis demonstrated that ADAM12 expression at the cell surface 
was significantly higher in claudin-low cell lines (Figure 2.1C). Basal-like and luminal breast 
cancer cell lines only showed moderate expression of ADAM12. Together, these data imply that 
 57 
high ADAM12 expression is associated with the claudin-low molecular subtype breast cancer. 
Claudin-low cancers are enriched in cancer stem-like features (Prat et al., 2010). Given the 
significant increase of ADAM12 levels in the claudin-low subtype of breast cancer, we decided 
to examine the biological significance of ADAM12 in this type of breast cancer, using 
representative triple-negative breast cancer cell lines SUM159PT and Hs578T. 
ADAM12 maintains the migratory and invasive properties of TNBC cell  
To investigate the role of ADAM12 in migration and invasion of triple-negative breast 
cancer cells in vitro, we established a stable SUM159PT cell line with inducible lentiviral-
mediated ADAM12 shRNA expression system (Figure 2.8A). Puromycin-resistant SUM159PT 
cells were selected for the following experiments. SUM159PT shADAM12 and shControl cells 
were treated with 1µg/ml Doxycycline (Dox) to induce ADAM12 shRNA. Expression of red 
fluorescent protein (RFP) was induced approximately 48h post-infection and served as an 
internal indicator of the expression of shRNAs (Figure 2.8C).  Significant decrease of both 
ADAM12 mRNA and protein levels was observed 4 days after Dox (Figure 2.8B-C). 
Proliferation assays showed that doxycycline-inducible ADAM12 knockdown did not affect the 
growth rate of SUM159PT in 2D culture compared to the cells with non-targeting control 
shRNA expression after Dox treatment (Data not shown). However, down-regulated ADAM12 
expression resulted in a significant reduction of transwell migration of SUM159PT in response 
to an FBS gradient (Figure 2.2A).  
To measure the effect of ADAM12 down-regulation on invasion, we seeded SUM159PT 
cells with or without ADAM12 KD into Matrigel and observed the formation of invasive 
branching structures 6 days post-seeding. Matrigel provides a three-dimension environment 
similar to the extracellular matrix, which allows the cells to attach and grow (Kleinman & 
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Martin, 2005). The colonies formed by SUM159PT cells with induced ADAM12 shRNA had a 
more round shape and smooth edges; whereas the colonies formed by cells with ADAM12 
expression showed more aggressive branching structures (Figure 2.2B). These results 
demonstrated that the ability of SUM159PT cell to invade Matrigel was markedly impaired upon 
ADAM12 knockdown (Figure 2.2B).  
Loss of ADAM12 reduces anchorage-independent growth and sphere formation by 
TNBC cells  
Next, we tested the function of ADAM12 in TNBC cells using 3D suspension culture in 
the presence of 1% methylcellulose. Sphere formation assay showed that decreased ADAM12 
expression in SUM159PT cells resulted in reduced mammosphere formation (Figure 2.3C), 
which indicated that SUM159PT cells with ADAM12 expression possess the ability of 
anchorage-independent growth. We further examined the effect of ADAM12 on apoptosis 
induced by detachment. DNA fragmentation, an indicator of the extent of apoptosis, was 
measured by Cell Death ELISA kit. SUM159PT cells with ADAM12 KD gave a striking 
increase of DNA fragmentation 24 hours post-seeding in suspension (right panel in Figure 2.3D, 
* P < 0.05). 
A time course study of apoptosis showed that SUM159PT cell underwent apoptosis upon 
detachment. Down-regulation of ADAM12 robustly reduced the ability of SUM159PT cells to 
resist death under the suspension conditions, as the DNA fragmentation of cells with ADAM12 
KD was considerably higher than cells with ADAM12 expression left panel in Figure 2.3D, * P 
< 0.05).  These findings are consistent with the results of the sphere formation assay. Altogether, 
our data showed that ADAM12 plays an indispensible role during maintaining the 
aggressiveness of triple-negative breast cancer cells in culture. 
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ADAM12 KD reduces the cancer stem cell subpopulation of TNBC cells 
To answer the question of whether ADAM12 would affect the population of tumor-
initiating cells in TNBC, we measured the cancer stem cell markers (ALDH and CD24CD44) of 
two TNBC cell lines, SUM159PT and Hs578T, after ADAM12 knockdown by siRNA. We were 
first looking at the expression of aldehyde dehydrogenase (ALDH), which is a hallmark of 
cancer stem cells. Previous studies showed that cancer stem cells have enhanced ALDH enzyme 
activity. Therefore, we measured the percentage of ALDEFLUOR-positive (ALDEFLUOR+) 
cells using the ALDEFLUOR kit and flow cytometry. ADAM12 KD diminished the 
ALDEFLUOR+ subpopulation by ~2 fold (Figure 2.3A-C) in SUM159PT.  
To confirm the result of ALDEFLUOR assay, we further examined other cancer stem cell 
markers, CD24 and CD44, in SUM159PT and Hs578T cells after ADAM12 KD. We found that 
down-regulated ADAM12 expression resulted in a decrease of CD44+/CD24-/low populations in 
both cell lines (Figure 2.4A-D). Consistently, the non-cancer stem-like cell population, 
CD44+CD24+ population, increased approximately 4 fold after ADAM12 down-regulation in 
SUM159PT cells (Figure 2.4C, *** P < 0.001) and 1.5 fold in Hs578T cells (Figure 2.4D, * P < 
0.05). These date are consistent with the results of ALDEFLUOR assay, which suggests that 
ADAM12 regulates cancer stem-like phenotype in TNBC cells. 
ADAM12 KD abrogates tumor-initating potential of TNBC cells in vivo 
Next, we tested the effect of ADAM12 KD on the tumor-initiating abilities of 
SUM159PT cells in vivo using a limiting dilution assay. Stable SUM159PT cells with Tet-On 
shADAM12 or shControl systems were treated with Dox (1µg/ml) for 4 days. Single cell 
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solutions of SUM159PT shADAM12 ± Dox and shControl ± Dox cells were injected into the 
mammary fat pad of female NOD-SCID mice at different amounts (102-104 cells, n = 6/dilution, 
Figure 2.5A). Mice injected with doxycycline-treated cells were fed with a customized diet 
containing doxycycline. Tumor formation was monitored every three days for three weeks. The 
tumor-initiating frequency and P values were calculated using the ELDA algorithm (Extreme 
Limiting Dilution Assay) (Hu & Smyth, 2009). SUM159PT cells with ADAM12 KD exhibited a 
markedly attenuated tumor occurrence. The frequency of tumor-initiating cells in SUM159PT 
cells with ADAM12 KD was approximately 4 times lower than that in SUM159PT shControl 
cells treated with Dox (Figure 2.5A, * P = 0.042). 
The effect of ADAM12 KD on the tumor growth rates in vivo was investigated by 
injecting 105 cells into the mouse mammary fat pad (n = 6/group).  Tumor volumes at the 
injection sites were checked every three days. Tumors started to develop about 14 days post-
injection. The tumor growth rate of SUM159PT with ADAM12 KD (Figure 2.5C, shADAM12 
+Dox, *** P < 0.0001) was significantly slower than the cells with normal ADAM12 expression 
(Figure 2.5C, shADAM12 –Dox). In contrast, there was no obvious difference between 
SUM159PT shControl cells with or without doxycycline treatment (Figure 2.5D). Representative 
tumor pictures of all four groups are shown in Figure 2.5B and D. In all, these data demonstrate 
that down-regulation of ADAM12 does not only reduce tumor occurrence, but it also delays 
tumor growth in vivo. These findings also confirmed that the regulation of ADAM12 is 
biologically significant in vivo. 
ADAM12 modulates cancer stem cells in TNBC through the EGF signaling pathway 
Next, we asked the question of how ADAM12 regulates cancer stem cell phenotype in 
TNBC. In order to answer this question, we performed RNA-sequencing of SUM159PT 
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shADAM12 and shControl cells, with and without Dox treatment. RNA extraction and data 
analysis were performed by Dr. Sara Duhachek-Muggy. To account for possible effects of 
doxycycline treatment or viral infection on gene expression, all genes that were changed by 
control treatments were excluded from the analysis (Figure 2.6A). At the end, forty-five genes 
were found differently expressed after ADAM12 KD in SUM159PT cells (Figure 2.6B).  These 
forty-five genes were analyzed by the Ingenuity Pathway Analysis (IPA) software, which would 
not only calculate what canonical pathways were enriched in our data set, but would also predict 
the possible upstream transcriptional regulators that might be the cause of the observed gene 
expression changes. The statistically significant upstream regulators, for which the Z-score of 
change was ≥2, are shown in Figure 2.6C. Interestingly, EGFR is one of the regulators 
discovered by the IPA analysis. Our previous work showed that overexpressed ADAM12 
induced higher EGFR phosphorylation in a mouse xenograft breast cancer model and that 
ADAM12 expression was highly correlated with EGFR phosphorylation in human breast tumors 
(Li et al., 2012). Taken together, these data suggest that ADAM12 might regulate the cancer 
stem cell phenotype in TNBC through the EGF signaling pathway. 
To test this hypothesis, we first examined the CD24+CD44+ subpopulation in SUM159PT 
after inhibiting the EGF signaling pathway. Remarkably, CD24+CD44+ subpopulation was 
robustly increased by treating SUM159PT cells with 1µM Erlotinib, a potent EGFR inhibitor, for 
3 days. (Figure 2.7A). This increase of CD24+CD44+ by Erlotinib was similar to the up-
regulation caused by ADAM12 knockdown using siRNAs (Figure 2.7B), which suggested that 
ADAM12 down-regulation and Erlotinib might have the same biological consequences.  This 
finding also indicated that reduced ADAM12 expression might have an inhibitory effect on EGF 
signaling pathway in SUM159PT cells, which was consistent with our IPA upstream regulator 
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analysis. Thus, to examine this possibility, we tested whether adding exogenous EGF would 
abolish the increase of CD24+CD44+ subpopulation caused by ADAM12 down-regulation. We 
transfected SUM159PT cells with siADAM12#1, siADAM12#2, and siControl#3 and then cells 
were treated with and without 20ng/ml EGF for 4 days. Notably, activation of EGFR with 
exogenous EGF blocked the reduction of CD44+/CD24-/low cells in response to ADAM12 
knockdown (Figure 2.7C-D). Thus, ADAM12 seems to act as an upstream activator of EGFR, 
which in turn promotes the CD44+/CD24-/low stem cell-like phenotype in SUM159PT cells.  
 
 Discussion 
Genetic studies have proved that TNBCs are heterogeneous (Prat & Perou,  2011). Most 
of the triple-negative breast tumors fall into either the basal-like (~70%) or the claudin-low 
subtypes (~25-39%). Claudin-low tumors are mostly TNBCs (61-71%) and marked by the low 
expression of genes regulating cell-cell tight junctions and epithelial cell adhesion, such as E-
cadherin, claudins, and EpCAM (Prat et al., 2010). Breast tumors of this subtype commonly 
feature low luminal/epithelial differentiation, they have the signature of epithelial-to-
mesenchymal transition (EMT), and they have potent tumor-initiating capabilities (Prat & Perou, 
2011). All these features may contribute, either individually or together, to the enhanced 
metastatic potential of breast cancer. In this study, we used SUM159PT and Hs578T, triple-
negative breast cancer cell lines, which are also of claudin-low subtype signature, to study the 
role of ADAM12 in tumor-initiating cells of TNBC.  
Previously, we found that the level of ADAM12 was strongly associated with decreased 
metastasis-free survival rate in TNBC and that the expression of ADAM12 was significantly 
upregulated in TNBC patients with distant metastasis (Li et al., 2012). Besides, ADAM12 was 
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shown to be associated with breast tumor-initiating phenotype, suggesting an active role of 
ADAM12 in breast cancers with enhanced metastasic phenotype (Li et al., 2013). However, our 
previous studies did not answer the question of whether ADAM12 was the causation of distant 
metastasis in TNBC nor address a role of ADAM12 in maintaining the BTIC phenotype. Our 
current report is the first one to demonstrate that ADAM12 may maintain and regulate cancer 
stem like phenotype in TNBC through the EGFR signaling pathway and can be considered a 
potential therapeutic target in BTICs. 
Patients with TNBC have a higher risk of an early relapse and a tendency of visceral 
metastasis as well as brain metastasis (Kim et al., 2013). In order to metastasize to distant sites, 
caner cells first need to acquire the ability to invade through the epithelial tissues and penetrate 
into the blood vessels by undergoing epithelial-to-mesenchymal transition (EMT) (Tsai & Yang, 
2013). Then, the transformed cancer cells escaping from the primary site travel along the 
circulating system to their destination and form metastatic colonies. This process requires the 
cancer cells not only to survive but also to be able to proliferate upon detachment from the 
extracellular matrix. Using a Tet-On system, we showed that down-regulation of ADAM12 in 
SUM159PT cells resulted in a substantial decrease of cell survival under detachment conditions. 
Besides, the sphere formation assay indicated that ADAM12 also facilitated the proliferation of 
SUM159PT cells deprived of the extracellular matrix. Based on the fact that the expression 
levels of ADAM12 have been shown to be strongly associated with the phosphorylation of 
EGFR in TNBC (Li et al., 2012), and the fact that the activation of EGFR signaling triggers the 
expression of the genes that act against apoptosis and promote cell survival (Han & Lo, 2012), it 
is reasonable to speculate that ADAM12 confers apoptosis resistance and anchorage-independent 
growth on TNBC cells by providing pro-survival signals through EGFR signaling pathway and, 
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therefore, maintain the enhanced metastatic phenotype of TNBC. This hypothesis was supported 
by Ingenuity Pathway Analysis (IPA) based on our RNA-sequencing data, which showed that the 
gene expression change pattern of ADAM12 down-regulation is similar as the inhibition of 
EGFR signaling pathway (Figure 2.6-7).  
Scientific literature has shown that tumor-initiating cells are the drive of tumor formation 
and they are responsible for the tumor relapse. CD44+CD24-/low surface antigenic phenotype and 
aldehyde dehydrogenase (ALDH) activity are well-established hallmarks of cancer stem-like 
cells and have been demonstrated to be strongly associated with the tumor/metastasis initiating 
capabilities of cancer cells (Perou, 2011; van den Hoogen et al., 2010; Huang et al., 2009; Ponti 
et al., 2005). Using TNBC cell lines SUM159PT and Hs578T, we are the first ones to illustrate 
that ADAM12 down-regulation alone efficiently decreased the ALDH+ and CD44+CD24-/low 
subpopulations in TNBC cells. We further confirmed the effect of ADAM12 on tumor-initiating 
frequency in vivo by limiting dilution assay (LDA). Limiting dilution assay is a well-established 
method designed to quantitatively measure the frequency of tumor-initiating cells in the bulk of 
original tumor by injecting increasing doses of tumor cells into animals (Ploemacher et al., 1989; 
O’Brien et al., 2010). We induced ADAM12 knockdown by a doxycycline inducible shRNA 
system, injected 100, 1000, 10000 SUM159PT cells into the fourth mammary fat pad of NOD-
SCID mice, and monitored tumor formation. Data were uploaded to ELDA software (Hu & 
Smyth, 2009) to calculate the frequency of SUM159PT cells after eliminating ADAM12. The 
result showed that the absence of ADAM12 significantly decreased the frequency of tumor 
initiating cells (Figure 2.5, ~3.8 times lower, P = 0.042 compared to the control cells treated with 
doxycycline), as well as the tumor growth in SUM159PT cells. Altogether, these results suggest 
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that ADAM12 is not only associated with tumor initiating phenotype, but it is also an active 
player in the regulation of cancer stem-like cell populations in TNBC. 
It has been widely accepted that the EMT program is the main process by which cancer 
cells acquire stem-like properties. Gupta and his group showed that breast cancer cells acquired 
CD44+CD24-/low or CD49fhighEpCAM- stem-like phenotype while undergoing EMT (Gupta et al. 
2009).  Besides, breast cancer cells with stem-like traits had high level of EMT-inducing 
transcription factors, such as ZEB1&2, Snail, and TWIST (Perou, 2011). Given the fact that high 
expression of mesenchymal markers is one of the main characters of claudin-low breast cancer 
(Prat et al., 2010) and that the expression of ADAM12 is induced by EMT in breast cancer cell 
lines (Li et al., 2013), we initially hypothesized that ADAM12 regulates stem-like cells in TNBC 
through TGFβ-mediated EMT. To this end, we first treated SUM149PT, a breast cancer cell line 
with low mesenchymal features, with TGFβ. No change of CD44+CD24-/low subpopulation in 
SUM149 cells was observed. Next, we treated SUM159PT cells with SB431542, a potent TGFβ 
receptor inhibitor, for 3 days, but we were not able to detect any changes in the CD44+CD24-/low 
subpopulation. Similar results were obtained when SUM159PT cells were transiently transfected 
with ZEB1 siRNAs for 4 days (data not shown). Interestingly, our IPA analysis based on the 
RNA-seq result of SUM159PT shADAM12 with and without doxycycline treatment did not 
identify the TGFβ pathway as one of the upstream regulators. All these results led us to propose 
that ADAM12 might regulate tumor-initiating cells through a pathway that is different from the 
TGFβ pathway. 
What is the novel pathway that is responsible for the regulation of stem-like phenotype 
mediated by ADAM12 in TNBC? Interestingly but not surprisingly, our IPA results based on 
RNA-seq data link the unique role of ADAM12 in stem-like cell regulation in TNBC to the 
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stimulation of EGFR signaling pathway. These results are consistent with and further support our 
previous findings that ADAM12 might be the main protease responsible for the activation of 
EGFR in TNBC. The role of EGFR signaling pathway in solid tumors has been exhaustively 
studied.  PI3K-Akt-mTOR, JAK2-STAT3, PLCγ-PKC, and RAS-MEK-MAPK (Han & Lo, 
2012) are the major downstream pathways regulated by EGFR, and these pathways are of 
importance in the progression, chemoresistance, and metastasis of various types of cancers. 
Activation of MAPK by EGFR not only promotes the degradation of pro-apoptotic protein BIM-
EL, but also increases the expression of pro-survival molecule BCL-XL (Buchheit et al., 2014). 
Activated mTORC1-p70 (S6K) by the EGFR-PI3K-Akt axis increases the survival rate under 
detachment conditions by suppressing autophagy (Avivar-Valderas et al., 2013). In addition to 
the fact that ADAM12 levels are correlated with the phosphorylation of EGFR in TNBC (Li et 
al., 2012), it is reasonable to speculate that the activation of EGFR could be the explanation for 
the increased apoptosis after ADAM12 KD under suspension conditions, which is further 
supported by the IPA results suggesting that the effect of ADAM12 KD is similar to the 
inhibition of the mTOR pathway.  
In addition to the promotion of anoikis resistance, the EGFR signaling pathway also 
contributes to the maintenance of the stem-like phenotype of cancer cells. EGFR-activated 
STAT3 induced TWIST upregulation and therefore promoted EMT by suppressing E-cadherin 
expression (Lo et al., 2007). Studies showed that the EGFR pathway regulated the stem-like 
traits in nasopharyngeal carcinoma and head and neck squamous cells. Furthermore, Yang’s 
group recently demonstrated that the EGFR-STAT3-SOX2 axis is required for the maintenance 
of the cancer stem cell phenotype of breast tumor cells (Yang et al., 2013). We further explored 
the effect of EGFR signaling inhibition on CD44+/CD24-/low subpopulation by incubating 
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SUM159PT cells with erlotinib, a potent EGFR inhibitor, which impairs the tyrosine kinase 
activity of EGFR. The effect of erlotinib was similar to the effect of ADAM12 KD. The effect of 
ADAM12 KD on CD44+/CD24-/low subpopulation was blocked when exogenous EGF was added 
to the cells.   
In the absence of HER2 overexpression in TNBC, it is plausible that the activation of 
EGFR would be the alternative driving force of cell survival and cancer progression. But the 
question that still needs to be addressed is how ADAM12 would affect the EGFR signaling 
pathway in TNBC. Most of the EGFR ligands, like EGF, heparin-binding EGF (HB-EGF), and 
transforming growth factor (TGF)-α are first synthesized and translocated to the cell surface as 
transmembrane precursors (Normanno et al., 2006; Han & Lo, 2012). The prototypes of these 
factors are cleaved and released from the cell surface by ADAMs. Studies showed that ADAM12 
was capable of shedding some of the EGFR ligands at the cell surface. A group at MIT has 
recently demonstrated that ADAM12 could cleave HB-EGF overexpressed in endometriotic 
epithelial cells (Díaz et al., 2013) . Moreover, ADAM12 has been reported to shed HB-EGF in a 
Notch-dependent manner in head and neck carcinomas, activating EGFR in a paracrine way and 
promoting cancer cell invasion (Díaz et al., 2013).  Combined with our previous finding that 
ADAM12 was the only ADAM member significantly upregulated in TNBC and associated with 
EGFR activation, we propose that ADAM12 might modulate EGFR signaling pathway in TNBC 
by cleaving and releasing EGFR ligands from cells. The identification of the ligands cleaved by 
ADAM12 in TNBC will illuminate the mechanism of the progression and metastasis of TNBC in 
more depth. 
In summary, our data suggest that ADAM12 may be a therapeutic target in TNBC. We 
showed that ADAM12 expression is abundantly expressed in claudin-low breast tumors at both 
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mRNA and protein levels. Importantly, we illustrated the important roles of ADAM12 in 
maintaining the aggressive phenotype of TNBC cells. In addition, our in vitro sphere formation 
assay and in vivo limiting dilution assay indicated that ADAM12 down-regulation dramatically 
decreased the tumor-initiating frequency of SUM159PT cells, suggesting that ADAM12 was 
required to maintain the tumor-initiating potential of TNBC cells. We further explored the 
molecular mechanisms and proved that ADAM12 maintained the tumor-initiating population 
through the EGFR signaling pathway. In all, our studies indicate that ADAM12 is a novel 
regulator of cancer stem-like phenotype and may serve as a potential diagnostic marker or a 
therapeutic target in TNBC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 69 
 
 
 
 
Figure 2.1 ADAM12 expression is upregulated in the claudin-low molecular subtype of 
breast cancer. 
(A) Heatmap showing ADAM12 mRNA expression levels in 295 breast cancer patients 
from the Netherland Cancer Institute (NKI) database (van de Vijver et al., 2002). Molecular 
subtypes of tumors are: B, basal; CL, claudin-low; HER2+, HER2-enriched, LumA, luminal A; 
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LumB, luminal B; NL, normal-like. (B) Expression levels of ADAM12 in 825 breast cancer 
patients from the TCGA database. (C) cell surface expression of ADAM12 protein in breast 
cancer cell lines was evaluated by flow cytometry. Hs578T, SUM1315MO2, BT549, and 
SUM159PT represent the claudin-low subtype, SUM102PT and SUM149PT represent the basal 
subtype, and MCF-7 and SUM225CWN are classified as luminal (Heiser et al., 2012; Prat et al., 
2010). 
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Figure 2.2  ADAM12 knockdown reduces cell migration, invasion, sphere formation, and 
resistance to anoikis. 
SUM159PT cells expressing tet-on ADAM12 shRNA (shADAM12) or control shRNA 
(shControl) were treated with doxycycline (Dox; 1 µg/ml) for 4 days. (A) cell migration was 
analyzed using Transwell assays. The data are shown as means ± SEM from 3 determinations. 
(B) representative phase-contrast images of SUM159PT cells embedded in 3D Matrigel are 
shown. Scale bar, 100 µm. (C) sphere formation was evaluated after seeding single-cell 
suspensions in serum-free sphere medium containing 1% methylcellulose into ultra-low 
attachment plates. After 10 days, spheres were visualized by phase contrast imaging, and the 
number of spheres with diameters > 50 µm were counted using ImageJ. The results are shown as 
means ± SEM obtained from 3 independent experiments. (D) anokis (apoptotic cell death upon 
detachment) was assayed using DNA fragmentation ELISA kit, as described in Methods. A time 
 72 
course of cell death was measured in triplicates (raw data, left), and the mean values of DNA 
fragmentation, ± SEM, after 24 h of detachment obtained in three independent experiments were 
calculated (right). *, P<0.05, n.s., non-significant. 
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Figure 2.3 ADAM12 knockdown reduces the population of ALDEFLUOR+ cells. 
(A-B) SUM159PT cells were transfected with a pool of four control non-targeting 
siRNAs (A) or a pool of four ADAM12 siRNAs (B). Five days after transfection, cells were 
stained with ALDEFLUOR reagent and analyzed by flow cytometry, as described in Methods. 
Plots show side cell scatter (SSC) versus BAA- fluorescence (BODIPY- aminoacetate, an 
intracellular reaction product of aldehyde dehydrogenase). ALDEFLUOR- (blue) and 
ALDEFLUOR+ (red) gates were identified after pre-treatment of cells with DEAB, an ALDH 
inhibitor. (C) percentages of ALDEFLUOR+ populations in SUM159PT cells were determined 
in four independent experiments. The results are shown as means ± SEM; *, P<0.05. 
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Figure 2.4 ADAM12 knockdown increases the subpopulation of CD24+/CD44+ cells. 
 (A-B) SUM159PT cells were transfected with a pool of four control non-targeting 
siRNAs (A) or ADAM12 siRNAs (B). Five days after transfection, cells were stained with PE-
conjugated anti-CD24 antibody and APC-conjugated anti-CD44 antibody and analyzed by flow 
cytometry. CD24-/CD44+ (green) and CD24+/CD44+ (red) and populations were identified based 
on isotype control antibody staining. (C-D) Percentages of CD24+/CD44+ populations in 
SUM159PT cells (C) and Hs578T cells (D) were determined in three independent experiments. 
The results are shown as means ± SEM, *, P<0.05. 
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Figure 2.5 ADAM12 knockdown reduces tumor growth in mice in vivo. 
(A) Tumor incidence in the limiting dilution assay. SUM159PT cells expressing tet-on 
shADAM12 or shControl were transplanted in the fourth mammary fat pad of NOD-SCID mice 
in limiting dilutions (10,000, 1,000, or 100 cells). To induce shRNA expression, cells were pre-
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treated with doxycycline (Dox; 1 µg/ml) for 4 days prior to transplantation, and Dox (2 g/kg) was 
then continually administered in the diet. The presence of palpable tumors was determined 3 
weeks after cell transplantation. The frequency of breast tumor initiating cells (BTICs) and P-
values for the statistical significance between groups were calculated using extreme limiting 
dilution analysis (ELDA, http://bioinf.wehi.edu.au/software/elda/) (Hu & Smyth, 2009). (B-D) 
representative tumors formed 38 days after injection of 105 cells by SUM159PT_shADAM12 
cells (B) or SUM159PT_shControl cells (D). (C-E) tumor growth was monitored for a period of 
0-38 days and tumor volumes were evaluated using caliper, as described in Methods. Nonlinear 
regression curves were fitted using GraphPad software.  
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Figure 2.6 RNA sequencing (RNA-Seq) analysis of the gene expression (GE) changes 
induced by ADAM12 knockdown in SUM159PT cells.  
(This work was done by Dr. Sara Duhachek-Muggy.) 
(A) A diagram summarizing the design and outcome of the RNA-Seq experiment. Genes 
differentially expressed in tet-on shADAM12 cells treated vs not treated for 6 days with 1 µg/ml 
Dox are shown in blue (a). Genes differentially expressed in tet-on shControl cells treated vs not 
treated with Dox are shown in green (b); these genes represent a negative control for genes 
shown in blue. Genes differentially expressed in tet-on shADAM12 vs shControl cells treated 
with Dox are shown in red (c). Genes differentially expressed in tet-on shADAM12 vs shControl 
cells not treated with Dox are shown in yellow (d); these genes represent a negative control for 
genes shown in red. (B) Heatmaps of differentially expressed genes in response to ADAM12 
KD. Compared are shADAM12 cells with vs without Dox treatment (left) and shADAM12 vs 
shControl cells treated with Dox (right). Only 45 differentially expressed genes common to the 
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(a) and (c) comparisons, after elimination of genes present in control (b) and (d) comparisons, 
are included. (C) The results of the Ingenuity Pathway Analysis (IPA) Upstream Regulator 
analysis. Potential upstream regulators with an overlap P‐value < 0.05 and an activation ∕z∕ 
score > than 2 are shown. 
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Figure 2.7 ADAM12 controls the population of CD24+/ CD44+ cells via regulation of EGFR.  
(A-B) Erlotinib mimics the effect of ADAM12 reduction on the population of 
CD24+/CD44+. SUM159PT grown in complete medium were treated for 24 h with 1 µM 
erlotinib, an EGFR inhibitor. Cell surface expression of CD24 and CD44 was analyzed by flow 
cytometry. (B) The effect of erlotinib on the CD24+/CD44+ populations in SUM159PT cells was 
quantified based on three independent experiments. (C) Exogenously added EGF blocks the 
effect of ADAM12 KD on CD24+/CD44+ populations. SUM159PT were transfected with 
siControl or with two different siRNAs targeting ADAM12. Three days later, cells were 
incubated with or without 20 ng/ml EGF in complete media for additional 24 h and analyzed for 
CD24 and CD44 expression. (D) The effect of exogenous EGF on CD24+/CD44+ populations, 
determined based on four independent measurements. 
 
 
 81 
 
 
Figure 2.8 Doxycycline-inducible ADAM12 knockdown in SUM159PT cells. 
(A) Diagram of the doxycycline-inducible lentiviral shRNA construct targeting 
ADAM12. 5’-LTR, 5’-long terminal repeat; TRE, tetracycline-inducible promoter; tRFP, turbo 
red fluorescent protein; miR30-5’ and shERp57/shPDI/shERp44, micro-RNA-30 adapted 
shRNA targeting ERp57/PDI/ERp44; Ubc, human ubiquitin C promoter; rtTA3, reverse 
tetracycline-transactivator 3; IRES, internal ribosomal entry site; Puro, puromycin resistance 
gene; 3’-LTR, 3’-long terminal repeat. (B-C) Validation of ADAM12 knockdown. Stably 
transduced SUM159PT_shADAM12 and SUM159PT_shControl cells were incubated for 4 days 
with or without 1 µg/ml of doxycycline. (B) ADAM12 mRNA levels were quantified by qRT-
PCR. (C) Cell surface expression of ADAM12 was examined by flow cytometry.   
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Chapter 3 - ADAM12 regulates TGFβ signaling pathway by 
modulating TGFBR1 mRNA expression in breast cancer cells 
 
 Abstract 
TGFβ signaling facilitates breast tumor progression at late stages of the disease through 
various mechanisms, such as promoting extracellular matrix degradation and angiogenesis. 
TGFβ induces the expression of ADAM12 at both the transcriptional and translational levels. 
Interestingly, studies have also shown that ADAM12 overexpression enhances TGFβ signaling 
through interactions with TGFβR2 in early endosomes. However, little effort has been made to 
illustrate the effect of ADAM12 on TGFβ signaling at the endogenous ADAM12 expression 
level in breast cancer cells. In the present study, we investigated the role of ADAM12 in the 
regulation of TGFβ signaling in breast cancer cells using a doxycycline inducible shRNA 
knockdown system. The loss of ADAM12 expression significantly decreased the activation of 
both SMAD-mediated and SMAD-independent TGFβ downstream signaling pathways, and 
reduced the expression level of TGFβR1. Furthermore, we found that ADAM12 mRNA levels 
were strongly associated with the TGFβ gene signature in breast cancer patients. In conclusion, 
our study describes a novel mechanism by which ADAM12 regulates the activation of TGFβ 
signaling in breast cancer cells.  
 
 Introduction 
The TGFβ signaling pathway plays unique and context-dependent roles in cancer 
progression (Massagué et al., 2012; Akhurst & Padgett, 2015). As a tumor suppressor, TGFβ 
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signaling inhibits proliferation of normal epithelial cells and cancer cells at early stages, whereas 
in late stage cancers, TGFβ signaling promotes cancer progression, angiogenesis, and 
malignancy (Gomes et al., 2012; Bierie & Moses, 2010; Janda et al., 2002). Tumor-promoting 
functions of TGFβ are related to its capability of inducing epithelial-to-mesenchymal transition 
(EMT) (Xu et al., 2009). Many reports have shown that TGFβ signaling is associated with poor 
prognosis, high risk of metastasis, and poor therapy response in different types of cancers (Elliott 
& Blobe, 2005; Biswas et al., 2006; Bhola et al., 2013; Li et al., 2013).  
The activation of TGFβ signaling pathway requires the binding of the TGFβ family 
ligands to the pre-formed TGFβR2 homodimer at the cell surface (Derynck et al., 2001). The 
complex of TGFβ and TGFβR2 further recruits TGFβR1, forming a tetramer complex, which 
allows the activation of TGFβR1 by TGFβR2 (Massagué & Chen, 2000). Once activated, 
TGFβR1 phosphorylates the receptor-regulated SMADs and transduces the signaling into the 
interior of the cells (Massagué & Chen, 2000). Thus, the regulation of TGFβ receptor availability 
at the cell surface is one of the regulatory mechanisms controlling the activation of the TGFβ 
signaling pathway (Rojas et al., 2009). TGFβR2 has been extensively studied due to the fact that 
it is constitutively active and is required for the activation of TGFβR1.  The expression of 
TGFβR2 can be regulated at the protein level by endocytosis (Hayes et al., 2002; Di Guglielmo 
et al., 2003), as well as at the transcriptional level by EGF/PI3K/Akt pathway and and 
microRNAs (Yamane et al., 2003; Liang et al., 2015; Zhong et al., 2012). Though TGFβR1 
(type I TGFβ receptor) is essential to activate the SMAD-dependent signaling pathway, there is 
very limited knowledge on the regulation of TGFβR1 (O’Brien et al., 2015).  
ADAM12 (A Disintegrin And Metalloprotease 12) is a membrane-anchored protease 
whose expression is positively regulated by TGFβ signaling at both the transcriptional and the 
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translational level in breast cancer cell lines (Li et al., 2013; Ruff et al., 2015). A previous study 
showed that ADAM12 increased TGFβR2 in early endosomes and enhanced the stability of 
TGFβR2 by preventing the receptor from interactions with SMAD7 and by blocking its 
degradation (Atfi et al., 2007). However, this study was conducted in ADAM12 overexpression 
cell models, which may not accurately mimic the effect of the endogenous ADAM12 on TGFβ 
receptors. In the current study, we have studied the role of ADAM12 in the regulation of TGFβ 
signaling pathway in breast cancer cells using a doxycycline inducible shRNA system to 
decrease ADAM12 expression. Our study describes a novel mechanism by which ADAM12 
regulates the TGFβ signaling pathway through modulating the mRNA level of TGFβR1. 
 
 Materials and Methods 
 Cell cultures and reagents 
SUM149 and SUM159PT cells (Asterand, MI) were cultured in Ham’s F-12 medium 
supplemented with 5% fetal bovine serum (FBS), 10 mM HEPES, 5 µg/ml insulin, and 1 µg/ml 
hydrocortisone. SUM1315MO2 cells (Asterand, MI) were cultured in Ham’s F-12 medium 
supplemented with 5% FBS, 10 mM HEPES, 10 ng/ml epidermal growth factor, and 5 µg/ml 
insulin. BT549 cells (ATCC, VA) were cultured in RMPI1640 medium supplemented with 10% 
FBS and µg/ml insulin. MCF10DCIS.com (Asterand, MI) were cultured in 1:1 (v/v) Dulbecco’s 
Modified Eagle Medium (DMEM)/Ham’s F-12 containing 15 mM HEPES and supplemented 
with 5% horse serum and 29 mM sodium bicarbonate. HEK293T cells were cultured in DMEM 
medium containing 10% FBS, 6 mM Glutamine, 1% Penicillin/ Streptomycin, and 110 µg/ml 
sodium pyruvate. SUM102PT cell line was a gift from Dr. Fariba Behbod (University of Kansas 
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Medical Center) and were maintained in Ham’s F-12 medium containing 5% FBS, 1 µg/ml 
hydrocortisone, 5 µg/ml insulin, and 1% Penicillin-Streptomycin-Amphotericin B (PSA). 
ADAM12 siRNA smartpool, TGFBR1 siRNA smartpool, control siRNA smartpool #1, 
and DharmaFECT1 transfection reagent were obtained from GE Dharmacon. Total RNA was 
extracted using RNeasy kit from QIAGEN. Human recombinant TGFβ1 and methylcellulose 
stock solution was purchased from R&D System. SYBR Select Master Mix for CFX was 
obtained from Life Technologies. EZ-link N-hydroxysuccinimide-PEG12-Biotin was purchased 
from Thermo Scientific. Other chemicals used are polybrene (Sigma-Aldrich), doxycycline 
(Dox, Sigma-Aldrich), paclitaxel (Sigma-Aldrich), SB-431542 (EMD Bioscience), 4- (2-
Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF, Thermo Scientific), pepstatin 
(Roche), leupeptin (Roche), aprotinin (Roche), and 1,10-phenanthroline (Sigma-Aldrich). 
 Analysis of TGF-β gene expression signature 
Genes (n = 147) that are significantly regulated by TGFβ in at least 3 breast cell lines 
(Padua et al., 2008) were used to establish a TGF-β gene expression signature score. Data of up- 
(n = 98) and downregulated (n = 49) genes in this signature are retrieved from the  The Cancer 
Genome Atlas (TCGA, 593 patients) for the analysis. The TGF-β signature score “s” was 
calculated as: 
              s = ∑wixi/∑⏐wi⏐ 
 
where w is the weight +1 or -1, depending on whether the gene was up- or downregulated 
in the signature (Bhola et al., 2013) and x is the normalized gene expression. 
 
 
i i 
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 Lentiviral small hairpin RNA (shRNA) and generation of stable cell lines 
shRNA targeting ADAM12 and control shRNA sequences were excised from GIPZ 
Human ADAM12 shRNA (V2LHS_11814) and non-silencing control lentiviral shRNA  
(Thermo Scientific) and cloned into pINDUCER10 vector (Addgene) at the XhoI and MluI sites. 
Lentiviruses were produced by transfecting HEK293T cells with 
pINDUCER10_shADAM12/shControl, pMD2.G, and psPAX2 plasmids (Addgene) using Mirus 
TransIT transfection reagent (Mirus).  Conditioned medium containing viral partiles was 
harvested 48h after transfection. SUM159PT and BT549 cells were plated one day before 
infection at ~20% confluence. Conditioned medium containing viral particles was supplemented 
with 5ng/ml polybrene. Selection of stably transduced cells started 48 hours after infection using 
2µg/ml of puromycin and continued for 10 days. 
 Flow cytometry  
SUM159PT/BT549_shADAM12/shControl cells were incubated without or with 1µg/ml 
Dox for 4 days. Cells were trypsinized into a single cell suspension at 106 cells/100µl, washed 
with 3% BSA/DPBS, and incubated with monoclonal anti-ADAM12 antibody (R&D System; 
clone# 632525) or isotype control antibody (R&D System; clone #11711) at a dilution of 1:10 
for 30 minutes on ice. Cells were then washed 3 times, incubated with allophycocyanin (APC)-
conjugated anti-mouse antibodies (Jackson ImmunoRes) for 30 min on ice. Analysis was 
performed using a BD FACSCalibur flow cytometer.  
 Luciferase reporter analysis 
SUM159PT_shADAM12 cells were treated without or with 1µg/ml Dox for 4 continuous 
days. Cells were then transfected with SBE4-Luc (Addgene), p3TP-Lux, or NF-κB-Luc 
(pGL4.32, Promega) reporter plasmids (0.5 µg per well of a 6-well plate) using X-tremeGENE 
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HP DNA transfection reagent (Roche) at a 2:1 (reagent:DNA) ratio. A Renilla luciferase reporter 
construct, pRL-TK (Promega), was co-transfected with the reporter plasmid as a transfection 
control. Transfected cells were incubated with TGFβ1for 24 hours (0, 0.5, 1, and 2 ng/ml TGFβ1 
was used for SBE4-luc and NF-κB-luc reporter assays; 2ng/ml of TGFβ1 was applied to cells 
transfected with p3TP-lux reporter). Forty-eight hours after transfection, the cells were washed 
with DPBS and then lysed using 1X Passive Lysis Buffer (Promega). The lysates were analyzed 
for firefly and Renilla luciferase using the Dual Luciferase Reporter Assay Kit (Promega), 
according to the manufacturer’s instructions.   
 Quantitative real time PCR 
One microgram of the total RNA was reverse-transcribed using the SuperScript III First 
Strand Synthesis system (Invitrogen) and oligo(dT) primers. Quantitative real time PCR (qRT-
PCR) was performed using 15 µl in a 96-well format on a CFX96 cycler. The final reaction 
mixture contained 7.5 µl SYBR Select Master Mix for CFX, 6 µl diluted cDNA (1:10 for 
ADAM12 and TGFBR1 analysis and 1:100 for COL6A3, SERPINE1, WNT5A, β-ACTIN analysis) 
and 0.5 µM primers. The primers used were as follows: 
Table 3-1 Primer sequences. 
 
Type of primers Primer sequence 
ADAM12-L 
F 5’-AGC CAC ACC AGG ATA GAG AC-3’ 
R 5’-CGC CTT GAG TGA CAC TAC AG-3’ 
β- ACTIN 
F 5’-TTG CCG ACA GGA TGC AGA A-3’ 
R 5’-GCC GAT CCA CAC GGA GTA CT-3’ 
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TGFBR1 
F 5’-GCC AGT CCT AAG TCT GCA AT-3’ 
R 5’-GGT CTT GCC CAT CTT CAC A-3’ 
COL6A3 
F 5’-GTT CAG AGA GCT TCC CAA CA-3’ 
R 5’-TTC AGA CAC AAA ACG AAG CA-3’ 
SERPINE1 
F 5’-ATT GAT GAC AAG GGC ATG GC-3’ 
R 5’-TCT GAT TTG TGG AAG AGG CG-3’ 
WNT5A 
F 5’-AGG GCT CCT ACG AGA GTG CT-3’ 
R 5’-GAC ACC CCA TGG CAC TTG-3’ 
 
The PCR conditions were: 95°C, 15 s; 60°C, 15 s; 72°C, 60 s. At the conclusion of each 
run, a melt curve analysis was performed to ensure that a single product had been synthesized. 
The relative expression of ADAM12-L, normalized to ACTIN, was calculated using the 2-ΔΔCt 
method.  
 Immunoblotting 
Cells were treated with lysis buffer at 4°C for15 min. Lysis buffer contained 50 mM Tris-
HCl pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium 
dodecylsulfate, 5 mM EDTA, 1 mM 4- (2-Aminoethyl) benzenesulfonyl fluoride hydrochloride, 
5 µg/mL pepstatin, 5 µg/ml leupeptin, 5 µg/ml aprotinin, and 10 mM 1,10-phenanthroline. 
Extracts were centrifuged for 15 min at 13,000 rpm at 4°C. After centrifugation, the supernatants 
were mixed with 3xSDS sample loading buffer of twice volume as the lysate. For ADAM12 
Western blotting, the supernatants were incubated with concanavalin A agarose (Sigma; 50 µl 
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resin per 1 ml cell lysate) for 2 hours at 4°C post-centrifugation to enrich for glycoproteins. The 
resin was washed three times and the glycoproteins were eluted with 3xSDS sample loading 
buffer.  
For cell surface biotinylation, cells grown in 6 well-plates were washed with DPBS, then 
incubated at 4°C for 60 min with 2.5 mM EZ-link N-hydroxysuccinimide-PEG12-biotin (Pierce) 
in DPBS. Remaining free reagent was quenched using 100 mM glycine. After washing cells 
several times with DPBS, cell lysates were collected as described above, and a fraction was 
retained as the input sample. The remaining lysate was allowed to adsorb onto Neutravidin 
agarose resin (Pierce) for 60 minutes at 4°C. The resin was washed three times with lysis buffer, 
followed by elution with 3xSDS sample buffer.  
Proteins were resolved using SDS-PAGE (8% gel) and were transferred to a 
nitrocellulose membrane. The membrane was blocked using 5% non-fat milk and 0.3% Tween-
20 in DPBS. Primary antibody was diluted in blocking buffer and incubated with the membrane. 
The dilutions were: anti-ADAM12 antibody (Ab#3394, 1:10,000, Li et al., 2012); anti-α-tubulin 
(DM 1A, 1:40,000 dilution, Sigma-Aldrich); anti-TGFBR1 (V-22, 1:300, Santa Cruz); anti-
EGFR (D38B1, 1:5,000), anti-GAPDH (D16H11, 1:100,000), anti-phospho-SMAD2 
(Ser465/467, 138D4, 1:1,000) and anti-SMAD2/3 (D7G7, 1:1,000, Cell Signaling). Horseradish 
peroxidase-conjugated anti-mouse and anti-rabbit IgG were used as secondary antibodies. 
Detection was performed using the SuperSignal West Pico or Femto Chemiluminescent 
Substrate (Pierce).  
Mammosphere formation analysis 
SUM159PT_shADAM12 cells were first treated without or with 1 µg/ml Dox for 4 days 
and then with 10 nM Paclitaxel for 6 continuous days. Cells were detached with 0.25% trypsin/1 
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mM EDTA in DPBS and counted by Cellometer TM AutoT4 (Nexcelom Bioscience). Single cell 
suspensions of 1x106 cells/ml were first passed through cell strainer and then diluted to 3x103 
cells/ml with mammosphere media containing MEMB (Lonza), 20 ng/ml hEGF (Life 
Technologies), 20 ng/ml bFGF (Life Technologies), 4 µg/ml heparin (Sigma), 1xB27 (Life 
Technologies), and 1x Penicillin/Streptomycin (Lonza).  Cell numbers among different 
treatments were adjusted within 95~105% using CellTiter Glo kit (Promega) according to the 
manufacturer’s instructiosn.  Cell suspensions at final dilutions of 3x103 cells/ml were mixed 
with 3% methylcellulose (R&D Systems) at the ratio of 2:1. The solution was thoroughly mixed 
by vortexing and incubated at room temperature for 10 min. Five hundred µl of the mixture (103 
cells in 1% Methylcellulose) was seeded into one well of 24-well ultra-low attachment plate 
(Corning). After 7 days, cells were analyzed using a phase contrast microscopy and a 4x 
objective, and six randomly selected areas from each well were photographed. The number of the 
colonies in each image was analyzed by Image J. 
 Statistical analysis 
Pearson and Spearman correlation coefficient were calculated using the GraphPad Prism 
6.0 software. All reported P values are two-sided. Statistical significance between two data sets 
was evaluated by Student’s t-test. P values < 0.05 was considered statistically significant. 
 
 Results 
ADAM12 mRNA is correlated with the TGFβ signature and is induced by TGFβ in 
breast cancer cells 
We first examined the correlation of ADAM12 mRNA level with TGFβ-responsive gene 
signature score (Bhola et al., 2013) in 593 breast cancer patients (the UNC AgilentG4502A_07, 
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data available at The Cancer Genome Atlas, http://cancergenome.nih.gov). The TGFβ-responsive 
gene signature was first evaluated by Padua and his colleagues in four breast cancer cell lines 
(Padua et al., 2008). The signature includes one hundred fifty three genes that were significantly 
changed by TGFβ in at least two cell lines. Our analysis demonstrated that ADAM12 mRNA 
expression was strongly correlated with the TGFβ gene score in breast cancers (Spearman r = 
0.5765, P < 0.0001) (Figure 3.1A). 
Next, we asked whether ADAM12 is a TGFβ responsive gene or a regulator of TGFβ 
signaling in breast cancer cells. To this end, we measured ADAM12 mRNA in SUM159PT, 
SUM149PT, and SUM102PT cells after 3 days of  treatment with TGFβ using qRT-PCR. The 
results revealed that ADAM12 mRNA levels were significantly increased after TGFβ treatment in 
all three cell lines (P < 0.05) (Figure 3.1B). We also examined ADAM12 protein levels by 
Western blotting in breast cancer cells (SUM1315MO2, MCF10DCIS.com, SUM159PT, and 
SUM102PT) incubated with or without TGFβ. Consistent with our qRT-PCR results, ADAM12 
protein expression was strongly elevated by TGFβ treatment in all four cell lines (Figure 3.1C) 
compared to untreated cells. These results suggest that ADAM12 is induced by TGFβ signaling. 
 TGFβR1 expression is regulated by ADAM12 
A previous study has shown that ADAM12 enhances TGFβ signaling via modulation of 
TGFβR2 in the early endosomes (Atfi et al., 2007). Since the activation of TGFβ signaling 
requires both TGFβR1 and TGFβR2, we wondered whether ADAM12 regulates TGFβR1 in 
breast cancers. To address this question, we established SUM159PT and BT549 breast cancer 
cell lines stably expressing doxycycline inducible ADAM12 shRNA system (Figure 3.2A). Upon 
treating cells with doxycycline (Dox, 1µg/ml) for 4 days, ADAM12 expression was strongly 
downregulated in both cell lines (Figure 3.2B). 
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Interestingly, the amount of TGFβR1 protein (MW~58kDa) was decreased in both 
SUM159PT (Figure 3.2D) and BT549 cells (Figure 3.2F) after ADAM12 knockdown. The 
decrease of TGFβR1 protein was more pronounced after TGFβ treatment (Figure 3.2D-G). To 
confirm the specificity of anti-TGFβR1 antibody, we transfected SUM159PT and BT549 cells 
with siRNAs targeting TGFβR1. The blot showed that the band at ~58kDa was significantly 
decreased after treating cells with TGFβR1 siRNAs (Figure 3.2H). Furthermore, we performed 
cell surface biotinylation assay in BT549_shADAM12 cells after TGFβ treatment to measure the 
expression of TGFβR1 at cell surface. In agreement with our findings described above, 
ADAM12 knockdown decreased the amount of biotinylated TGFβR1 almost 2-fold compared to 
the control cells (Figure 3.2I). 
 ADAM12 knockdown attenuates TGFβ signaling  
To examine the effect of ADAM12 downregulation on TGFβ signaling, we first 
examined the phosphorylation of SMAD2 induced by TGFβ. ADAM12 knockdown was induced 
in SUM159PT by doxycycline treatment, which was then followed by treatment with different 
doses of TGFβ. Western blotting indicated that ADAM12 knockdown attenuated the 
phosphorylation of SMAD2 in response to TGFβ (Figure 3.3A).  
Next, we used dual-luciferase assay as an alternate approach to evaluate the inhibitory 
effect of ADAM12 knockdown on TGFβ signaling. We co-transfected SUM159PT_shADAM12 
cells with the SBE4-luc reporter and pRL-TK, a control Renilla luciferase reporter. Our result 
suggested that downregulation of ADAM12 efficiently diminished the increase of the SBE4-luc 
reporter activity in response to TGFβ (Figure 3.3B, P < 0.05). Interestingly, a strong decrease of 
SBE4-luc reporter activity was observed in cells with ADAM12 downregulation even in the 
absence of added TGFβ (Figure 3.3B). The results obtained for another TGFβ signaling reporter, 
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p3TP-lux, was consistent with the SBE4-luc reporter showing the compromised reporter activity 
after reducing ADAM12 expression (Figure 3. 3C).   
Studies have shown that TGFβ-TGFβR1 regulates the NF-κB signaling pathway through 
the activation of TGFβ-associated kinase1 (TAK1) in a SMAD-independent manner (Ataie-
Kachoie et al., 2013; Gingery et al., 2008). Here, we used a NF-κB-luc reporter to test whether 
ADAM12 knockdown would affect the activation of the TAK1-mediated non-canonical TGFβ 
signaling pathway. Our results demonstrated that SUM159PT cells with ADAM12 
downregulation had a significant decrease of the NF-κB-luc reporter activation in response to 
different doses of TGFβ (Figure 3.3D), suggesting that ADAM12 regulates non-canonical TGFβ 
signaling pathways.  
Next, we asked whether ADAM12 knockdown had an effect on TGFβ responsive genes. 
To answer this question, we checked the expression of several typical TGFβ target genes in 
SUM159PT cells. COL6A3, SERPINE1, and WNT5A are well-studied TGFβ targeted genes and 
their protein products play important roles in cell-cell adhesion, fibrinolysis, proliferation, 
migration, and other cellular events (Verrecchia et al., 2001; Otsuka et al., 2006; Kikuchi et al., 
2012). First, we downregulated ADAM12 in SUM159PT cells and then treated cells with TGFβ. 
At the end of the experiment, total RNA was extracted and TGFβ  target gene expression was 
analyzed by qRT-PCR. The results demonstrated that ADAM12 knockdown significantly 
reduced the increase of COL6A3 (Figure 3.3E, P < 0.01), SERPINE1 (Figure 3.3F, P < 0.05), 
and WNT5A mRNA (Figure 3.3G, P < 0.01) in response to TGFβ. Together, these results suggest 
that ADAM12 is not only associated with the TGFβ gene signature, but it is also actively 
involved in the regulation of TGFβ signaling. 
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ADAM12 regulates TGFβR1 expression through a TGFβ independent pathway 
Next, we asked the question of how ADAM12 regulates TGFβR1 expression. First, we 
tested the effect of ADAM12 knockdown on the stability of TGFβR1 protein. Our 
cycloheximide chasing experiment showed no significant change of TGFβR1 expression when 
ADAM12 was downregulated (data not shown). Therefore, we investigated whether ADAM12 
knockdown affects TGFβR1 mRNA levels. Our qRT-PCR results indicated that TGFβ induced a 
significant increaseof TGFβR1 mRNA  (Figure 3.4A, ~ 2.6-fold, P < 0.01). ADAM12 
knockdown not only completely diminished the elevation of TGFβR1 mRNA triggered by TGFβ 
(Figure 3.4A, P < 0.0001) but also was able to decrease the basal level of expression of TGFβR1 
mRNA (with the absence of TGFβ) (Figure 3.4A, P < 0.01).  
Given the observation that TGFβR1 mRNA was responsive to TGFβ and that the loss of 
ADAM12 expression impairs the TGFβ signaling pathway, we speculated that ADAM12 might 
regulate TGFβR1 mRNA expression through the TGFβ signaling pathway, in a positive feedback 
loop. To address this hypothesis, we used SB-432542, a potent TGFβR1 inhibitor, to block the 
TGFβ pathway. Our rationale was that if ADAM12 regulated TGFβR1 mRNA through TGFβ 
signaling, the decrease of TGFβR1 mRNA caused byADAM12 downregulation should not occur 
in the presence of the inhibitor. Unexpectedly, we observed that ADAM12 knockdown was led 
to inhibition of TGFβR1 mRNA expression even in the presence of SB-431542 (Figure 3.4A, 
with no TGFβ P < 0.0001; with TGFβ, P < 0.05). Altogether, our results indicated that 
ADAM12 regulated TGFβR1 mRNA expression through a novel pathway that did not require an 
active TGFβR1. 
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 ADAM12 downregulation attenuates the sphere formation induced by TGFβ 
We asked about the biological consequence of the regulation of TGFβ signaling by 
ADAM12. It has been previously shown that TGFβ is a potent EMT inducer and increases the 
ability of cancer cells to form spheres under suspension conditions (Bhola et al., 2013). In 
addition, Bhola and coworkers showed that paclitaxel (PTX) treatment expanded cancer stem 
cell population in triple-negative breast cancers through TGFβ signaling. As a result, breast 
cancer cells after PTX treatment formed higher number spheres (Bhola et al., 2013).  
In this study, we downregulated ADAM12 expression in SUM159PT cells, treated the 
cells with TGFβ, and seeded single cell suspensions in 1% methylcellulose in ultra low-
attachment plate for sphere formation. We observed that ADAM12 knockdown efficiently 
diminished the effect of TGFβ on sphere size, further confirming that ADAM12 knockdown 
compromised cellular responses to TGFβ (Figure 3.5B, P < 0.05). When SUM159PT cells were 
incubated with PTX for 6 days, the surviving cells in which ADAM12 expression was reduced 
formed fewer spheres (Figure 3.5D) and the resulting spheres were smaller in size (Figure 3.5C). 
These results suggest that ADAM12 knockdown also impaired cellular responses to the 
endogenous TGFβ produced in response to PTX. 
 
 Discussion 
TGFβ signaling is an important promoter of tumor progression in late stage cancers 
(Gomes et al., 2012; Bierie & Moses, 2010; Massagué et al., 2012). As a potent EMT inducer, 
TGFβ signaling causes the loss of cell polarity, equips cells with mesenchymal characteristics, 
and prepares the microenvironment for tumor dissemination (Xu et al., 2009; Pickup et al., 2013; 
Papageorgis et al., 2015). Our analysis of the TCGA transcriptomic datasets for a large number 
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of breast tumors revealed that ADAM12 expression is strongly associated with the TGFβ gene 
signature. We further demonstrate that the loss of ADAM12 significantly impairs both SMAD-
dependent and SMAD-independent TGFβ signaling in breast cancer cells. Our study is the first 
report showing the role of ADAM12 in the regulation of TGFβ signaling in breast cancer cells, 
though overexpressed ADAM12 had been previously shown to contribute to TGFβ signaling in 
mouse myoblasts and liver carcinoma cells (Atfi et al., 2007).  
TGFβ receptors provide an important regulatory point for the activation of TGFβ 
signaling pathway (Rojas et al., 2009). Much attention has been focused on the regulation of 
TGFβR2 due to the fact that TGFβR2 is constitutively active and is required for the activation of 
TGFβR1 (Yamane et al., 2003; Liang et al., 2015; Zhong et al., 2012; Di Guglielmo et al., 
2003). ADAM12 has been previously demonstrated to enhance TGFβ signaling by increasing the 
amount of TGFβR2 in early endosomes as well as preventing TGFβR2 from interacting with 
SMAD7 for degradation (Atfi et al., 2007). The results of our current study uncover that 
ADAM12 positively regulates TGFβ signaling via modulating TGFBR1 mRNA levels. In the 
present study, the reduced ADAM12 expression caused a dramatic decrease of TGFβR1 at the 
protein level (Figure 3.2D-G, I), whereas TGFβR2 did not change (data not shown). At the 
mRNA level, the downregulation of ADAM12 attenuated TGFBR1 mRNA levels, and this effect 
was even more pronounced in the presence of TGFβ. Intriguingly, our results suggest that 
ADAM12 modulates TGFBR1 mRNA through a TGFβ signaling-independent manner, because a 
TGFβR inhibitor could not block the decrease of TGFBR1 mRNA mediated by ADAM12 
downregulation. A possible explanation for the discrepancy between our results and those by 
Atfi et al. is that the latter study was performed using ADAM12 overexpressing cells, which did 
not accurately replicate the effect of endogenous ADAM12. Besides, we did not observe any 
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change in TGFβR2 expression after ADAM12 knockdown, indicating ADAM12 might not 
participate in the stabilization of TGFβR2 in breast cancer cells. The question of whether 
ADAM12 regulates the expression of TGFβR2 at mRNA level needs to be further studied. 
Though TGFβR1 is a critical component of SMAD-dependent TGFβ signaling pathway, 
the current knowledge regarding the regulation of TGFβR1 is very limited. Studies have shown 
that endocytosis is a main regulator of TGFβR1 at the cell surface (He et al., 2015; Di Guglielmo 
et al., 2003; O’Brien et al., 2015). In addition, Notch signaling has been shown to upregulate the 
mRNA levels of TGFβR1 through inhibition of neuropilin-1 (Nrp1), a membrane receptor 
interacting with VEGF and other factors (Aspalter et al., 2015). Coincidentally, our previous 
work demonstrated that ADAM12 was able to cleave Notch receptor ligand Delta-like 1 and to 
activate Notch reporters (Dyczynska et al., 2007). More work is needed to unveil the TGFβ 
independent pathway through which ADAM12 modulates TGFBR1 mRNA levels. 
Given the fact that ADAM12 expression is also regulated by TGFβ (Li et al., 2013; Ruff 
et al., 2015), there is an interesting reciprocal relationship between ADAM12 and TGFβ 
signaling: ADAM12 is not only regulated by TGFβ signaling but it also potentiates TGFβ 
signaling. This effect is, to an extent, consistent with the observation that ADAM12 expression is 
particularly elevated in claudin-low subtype breast cancer (Li et al., 2013), which is 
characterized by high mesenchymal signatures and activation of the TGFβ pathway. 
In conclusion, our present study describes a new role of ADAM12 in the regulation of 
TGFβ signaling in human breast cancers. Importantly, the expression of ADAM12 significantly 
and positively regulates the activation of TGFβ signaling via modulation of TGFBR1 mRNA in 
breast cancer cells.  
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Figure 3.1 ADAM12 expression is positively associated with TGFβ signaling in human 
breast cancer.  
(Panel B was performed by Linda Alyahya.) 
(A) Correlation analysis between ADAM12 mRNA expression and the TGFβ gene 
signature scores of 593 breast cancer patients from the TCGA database. The TGFβ gene 
expression scores were calculated based on ref. Bhola et al., 2013 and Padua et al., 2008. (B) 
SUM159PT, SUM149PT, and SUM102PT cells were treated with 2 ng/ml TGFβ for 3 days. 
ADAM12 mRNA levels were measured by qRT-PCR and normalized to β-ACTIN. Fold change 
in TGFβ-treated cells versus no TGFβ treatment were shown as the average values ± SEM. (n = 
3; one sample t test, * P < 0.05). (C) ADAM12 protein levels before and after 3-day treatment 
with 2 ng/ml TGFβ in different cell lines were detected by Western blotting; Tubulin is a gel-
loading control. Arrows indicate the nascent and the mature forms of ADAM12, respectively. 
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Figure 3.2 ADAM12 downregulation decreases the expression of TGFβR1 in SUM159PT 
and BT549 cells.  
(A) A diagram of the doxycycline-inducible lentiviral shRNA construct targeting 
ADAM12. 5’-LTR, 5’-long terminal repeat; TRE, tetracycline-inducible promoter; tRFP, turbo 
red fluorescent protein; miR30-5’ and shADAM12, micro-RNA-30 adapted shRNA targeting 
ADAM12; Ubc, human ubiquitin C promoter; rtTA3, reverse tetracycline-transactivator 3; IRES, 
internal ribosomal entry site; Puro, puromycin resistance gene; 3’-LTR, 3’-long terminal repeat. 
(B, C) Validaton of ADAM12 knockdown. SUM159PT (B) and BT549 (C) cells expressing 
inducible ADAM12 shRNA (SUM159PT or BT549_shADAM12) were treated with 1 µg/ml 
Dox for 4 days. ADAM12 expression at the cell surface was measured by flow cytometry. (D-G) 
Stably transduced SUM159PT_shADAM12/shControl (D, E) and BT549_shADAM12/Control 
(F, G) cells were incubated for 4 days with 1 µg/ml of Dox, followed by 3-day TGFβ treatment. 
Cell lysates were analyzed by Western blotting using anti-TGFβR1 (TβR1) antibody; Tubulin is 
a gel loading control. Band intensities were measured using Image J. The average fold changes 
in TGFβR1 of SUM159PT (E) and BT549 (G) cells under each condition are shown as the 
average value ± SEM. (n = 3; unpaired Student t test, ** P < 0.01). (H) SUM159PT and BT549 
cells were transfected with a pool of four siRNAs targeting TGFβR1 or a pooled control siRNAs. 
Expression levels of TGFβR1were analyzed by Western blotting; GAPDH is a gel loading 
control. Arrow indicates the position of TGFβR1. (I) BT549_shADAM12/shControl cells were 
sequentially incubated with 1 µg/ml of Dox for 4 days and 2 ng/ml of TGFβ for 3 days. Cells 
were then incubated with NHS-PEG12-bition, followed by purification of biotinylated proteins 
using NeutaAvidin beads and Western blotting; EGFR is the positive control for biotinylation 
and Tubulin is a gel loading control. Band intensities were quantified by Image J. 
  
 106 
 
 
Figure 3.3 ADAM12 knockdown impairs SMAD-dependent and SMAD-independent TGFβ 
downstream signaling in SUM159PT cells.  
(Panel E-G were performed by Dr. Sara Duhachek-Muggy.) 
(A) Dox pre-treated SUM159PT_shADAM12 cells were incubated with 0, 0.1, 0.5, 1, 
and 2 ng/ml TGFβ for 3 days. Protein levels of phosphorylated SMAD2 and SMAD2 were 
analyzed by Western blotting using specific antibodies. (B-D) SUM159PT_shADAM12 cells 
were treated with 1 µg/ml Dox for 4 days and then were transfected with SBE4-Luc (B), p3TP-
Lux (C), or NF-κB-Luc (D) reporters, and a Renilla luciferase control vector. Transfected cells 
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were treated with different amounts of TGFβ for 24 hours and were collected for dual-luciferase 
gene reporter assay 48 hours after transfection. The activities of Firefly luciferase reporters were 
normalized to Renilla luciferase activity and were shown as the average value ± SEM (n = 3; 
unpaired Student t test, * P < 0.05, ** P < 0.01). (E-F) Dox pre-treated 
SUM159PT_shADAM12 cells were incubated with 2 ng/ml TGFβ for 3 days. COL6A3 (E), 
SERPINE1 (F), and WNT5A (G) mRNA expression levels were analyzed by qRT-PCR and 
normalized to β-ACTIN and to the control cells (with neither Dox nor TGFβ treatment). The fold 
changes are presented as the average values of three independent experiments ± SEM. (n = 3; 
one sample t test, * P < 0.05, ** P < 0.01).   
  
 108 
 
 
Figure 3.4 ADAM12 negatively regulates the expression of TGFBR1 mRNA in SUM159PT 
cells.  
(A) SUM159PT_shADAM12 cells were treated with 1 µg/ml Dox for 4 days and then 
incubated with TGFβ or SB431542, an inhibitor of TGFβR1, for 3 days. TGFBR1 mRNA 
expression levels were analyzed by qRT-PCR and normalized to β-ACTIN and to the control 
cells (with no treatments). The fold changes in TGFBR1 mRNA expression are presented as the 
average values of three independent experiments ± SEM (n = 3; unpaired Student t test, * P < 
0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001). (B) A diagram for the regulation of 
TGFBR1 mRNA by ADAM12 in breast cancer cells. TGFβR1-mediated TGFβ signaling 
activation induces the expression of TGFBR1 mRNA, which can be blocked by TGFβR1 
inhibitor SB431542. ADAM12 positively modulates TGFBR1 mRNA expression in a manner 
that is independent of TGFβ signaling. More data are needed to exclude the possibility that 
ADAM12 regulates TGFβ signaling via direct interaction with TGFβR1 at the protein level. 
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Figure 3.5 The effect of ADAM12 knockdown on mammosphere growth induced by TGFβ.  
(A) SUM159PT_shControl cells were pre-incubated for 4 days without or with Dox and 
were further grown for 10 days in mammosphere media in the absence or presence of 
doxycycline. Representative phase contrast and fluorescent images are shown. (B-D) 
SUM159PT_shADAM12 cells were pre-incubated for 4 days without or with Dox and then were 
further treated with vehicle, 2 ng/ml TGFβ, or 10 nM paclitaxel (PTX), respectively, for another 
6 days. Cells were seeded at the density of 1000 cells/well in a 24-well ultra-low attachment 
plates. After 7 days, spheres were visualized by phase contrast imaging and counted using Image 
J. (B, C) Size distribution of spheres formed after TGFβ (B) and paclitaxel (C) treatments are 
shown as box-and-whisker plots. Sphere diameters were determined using Image J. The results 
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were obtained in 3 independent experiments (n = 3; unpaired Student t test, * P < 0.05, **** P < 
0.0001). (D) The numbers of spheres formed after paxlitaxel treatment with diameters larger than 
50 µm were counted by Image J and are shown as the mean values ± SEM. (n = 3; unpaired 
Student t test, * P < 0.05). 
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Chapter 4 - Phenotypic diversity of breast cancer-related mutations 
in metalloproteinase-disintegrin ADAM12 
This chapter has been published in the following journal: 
Qi, Y., Duhachek-Muggy, S., Li, H., & Zolkiewska, A. (2014) Phenotypic diversity of 
breast cancer-related mutations in metalloproteinase-disintegrin ADAM12. PLoS ONE 
9(3): e92536. 
 
 Abstract 
Six different somatic missense mutations in the human ADAM12 gene have been 
identified so far in breast cancer. Five of these mutations involve highly conserved residues in 
the extracellular domain of the transmembrane ADAM12-L protein. Two of these extracellular 
mutations, D301H and G479E, have been previously characterized in the context of mouse 
ADAM12. Three other mutations, T596A, R612Q, and G668A, have been reported more 
recently, and their effects on ADAM12-L protein structure/function are not known. Here, we 
show that ADAM12-L bearing the G668A mutation is largely retained in the endoplasmic 
reticulum in its nascent, full-length form, with an intact N-terminal pro-domain. The T596A and 
R612Q mutants are efficiently trafficked to the cell surface and proteolytically processed to 
remove their pro-domains. However, the T596A mutant shows decreased catalytic activity at the 
cell surface, while the R612Q mutant is fully active and comparable to the wild-type ADAM12-
L. The D301H and G479E mutants, consistent with the corresponding D299H and G477E 
mutants of mouse ADAM12 described earlier, are not proteolytically processed and do not 
exhibit catalytic activity at the cell surface. Among all six breast cancer-associated mutations in 
ADAM12-L, mutations that preserve the activity - R612Q and L792F - occur in triple-negative 
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breast cancers, while loss-of-function mutations - D301H, G479E, T596A, and G668A - are 
found in non-triple-negative cancers. This apparent association between the catalytic activity of 
the mutants and the type of breast cancer supports a previously postulated role of an active 
ADAM12-L in the triple-negative breast cancer disease. 
 
 Introduction 
Disintegrin and metalloproteinase domain-containing protein ADAM12 is a member of 
the ADAM family of proteins that mediate cleavage of substrates at the cell surface and/or 
modulate intracellular signaling pathways (Edwards et al., 2008; Weber & Saftig, 2012). 
ADAM12 is highly up-regulated in human breast tumors (Iba et al., 1999; Kveiborg et al., 2005; 
Lendeckel et al., 2005; Mitsui et al., 2006; Bertucci et al., 2006; Turashvili et al., 2007; Roy & 
Moses, 2011). In triple-negative breast cancers (TNBCs, lacking estrogen receptor and 
progesterone receptor expression and ERBB2 gene amplification), high expression of ADAM12-
L, but not ADAM12-S, mRNA is associated with poor prognosis (Li et al., 2012). ADAM12-L 
and ADAM12-S are two different splice variants that encode the long, transmembrane protein 
isoform ADAM12-L and the short, secreted ADAM12-S, respectively (Kveiborg et al., 2008). 
Among thirteen different ADAM genes that encode catalytically active proteases 
(Edwards et al., 2008), ADAM12 is the most frequently somatically mutated gene in human 
breast cancers. As of September 2013, the COSMIC database (Catalogue of Somatic Mutations 
in Cancer, http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) listed 6 confirmed somatic 
missense mutations in the ADAM12 gene per a total of 1104 unique breast carcinoma samples 
analyzed. The frequencies of breast cancer-associated missense mutations in other genes 
encoding catalytically active ADAMs were: 1/973 in ADAM9, 1/973 in ADAM10, 1/1147 in 
 117 
ADAM17, 1/1010 in ADAM19, 1/973 (plus one nonsense mutation) in ADAM20, and 1/973 in 
ADAM30. No other missense/nonsense somatic mutations were reported for the remaining 
ADAM genes encoding catalytically active proteases (i.e., ADAM8, -15, -21, -28, -33, and 
ADAMDEC1). A relatively high frequency of mutations in the ADAM12 gene can be attributed 
to the fact that ADAM12 is located on human chromosome 10q26.2, in a region capable of 
forming highly stable secondary structures (Dillon et al., 2013). 
The six breast cancer-associated mutations in the ADAM12-L protein include the D301H 
mutation in the metalloproteinase domain, G479E in the disintegrin domain, T596A and R612Q 
in the cysteine-rich domain, G668A in the epidermal growth factor (EGF)-like domain, and 
L792F in the cytoplasmic tail (Sjoblom et al., 2006; Shah et al., 2012; Jiao et al., 2012) (Figure 
4.1A). We have previously shown that the D299H and G477E mutations in mouse ADAM12 
(which correspond to the D301H and G479E mutations in human ADAM12) are loss-of-function 
mutations that inhibit the intracellular trafficking and proteolytic activation of the nascent 
ADAM12 protein (Dyczynska et al., 2008). The L792F mutation in human ADAM12-L was 
reported not to affect protein processing, localization, or function (Dyczynska et al., 2008; Stautz 
et al., 2012). The other three mutations - T596A, R612Q, and G668A - have been identified 
more recently (Shah et al., 2012; Jiao et al., 2012), and their effects on the structure/function of 
ADAM12 are currently unknown. 
Here, we show that there is functional diversity between the three recently identified 
mutations. While ADAM12-L containing the G668A mutation is largely retained in the 
endoplasmic reticulum (ER) and is not proteolytically activated in the Golgi, the T596A mutant 
is properly trafficked and proteolytically processed but is still catalytically inactive. The R612Q 
mutant is trafficked, processed, active, and is indistinguishable from the wild-type (WT) 
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ADAM12-L. Taking into consideration all six known breast cancer-associated somatic mutations 
in ADAM12-L, we note an apparent association between the catalytic activity of ADAM12-L 
mutants and the molecular characteristic of the tumor. The two mutations that do not have any 
effect on ADAM12-L activity, R612Q and L792F, occurred in TNBCs. The four mutations that 
render ADAM12-L inactive, i.e., D301H, G479E, G668A, and T596A, were described in non-
TNBCs. This observation further suggests an important role of the catalytically active ADAM12-
L in the triple-negative breast cancer disease. 
 
 Materials and Methods 
Expression Constructs 
Retroviral expression vector ADAM12-L-pBABEpuro was used for the expression of the 
wild-type (WT) ADAM12-L protein. The D301H, G479E, T596A, R612Q and G668A point 
mutations were introduced by site-directed mutagenesis using the QuickChange kit (Stratagene). 
The entire lengths of all DNA inserts were sequenced to confirm that no other mutations were 
introduced during mutagenesis. The expression construct of Delta-like 1 (DLL1) in pIRESpuro 
vector was described earlier (Dyczynska et al., 2007). 
Cell Culture and Treatment 
Human MCF10A mammary epithelial cells (ATCC) were cultured in DMEM/F12 (1∶1) 
supplemented with 5% horse serum, 0.5 µg/ml hydrocortisone, 20 ng/ml human EGF, 10 µg/ml 
insulin, 100 ng/ml cholera toxin, and 1% penicillin/streptomycin. Retrovirus production and 
stable transduction of MCF10A cells with viruses encoding WT or mutant ADAM12-L, or with 
control viruses bearing empty pBABEpuro vector, were performed as described previously (Li et 
al., 2013). Transient transfections were performed using X-tremeGENE HP transfection reagent 
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(Roche). For protein stability assay, cells were treated with 10 µg/ml cycloheximide (EMD 
Millipore) in culture medium for indicated times. 
Antibodies 
Anti-ADAM12 rabbit polyclonal antibody (Ab 3394) specific for the cytoplasmic domain 
of human ADAM12-L was developed in our laboratory, as described (Li et al., 2012). The 
remaining antibodies were: anti-ADAM12 mouse mAb (R&D Systems; clone 632525, specific 
for the extracellular domain of ADAM12-L), anti-KDEL mouse mAb (clone 10C3, Enzo Life 
Sciences), anti-EGFR (D38B1) XP rabbit mAb (Cell Signaling), anti-phospho-EGFR (pY1173) 
rabbit polyclonal Ab (R&D Systems), anti-DLL1 rabbit polyclonal Ab (H-265, Santa Cruz 
Biotechnology), anti-β-actin mouse mAb (clone AC-15, Sigma), and anti-α-tubulin mouse mAb 
(clone DM 1A, Sigma). 
Immunofluorescence 
Stably transduced MCF10A cells were plated on glass coverslips placed in 6-well plates. 
Two days later, cells were fixed with 3.7% paraformaldehyde/DPBS for 20 min, followed by 
permeabilization with 0.1% Triton X-100/DPBS for 5 min. Coverslips were incubated with anti-
ADAM12-L polyclonal antibody (1∶500 dilution) and anti-KDEL antibody (1∶200 dilution), 
followed by incubation with rhodamine Red-X-conjugated anti-rabbit IgG antibody, Alexa 488-
conjugated anti-mouse IgG antibody, and DAPI. Immunofluorescence was examined using an 
Axiovert 200 inverted fluorescent microscope. 
Flow Cytometry 
Cells were trypsinized into a single cell suspension, washed with DPBS containing 3% 
BSA, and incubated with anti-ADAM12 monoclonal antibody or isotype control antibody (R&D 
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Systems, both at 1∶10 dilution) for 30 minutes on ice. Cells were then washed 3 times, 
incubated with allophycocyanin (APC)-conjugated anti-mouse antibodies (Jackson 
ImmunoResearch; 1∶100) for 30 min on ice, washed again, and then incubated with 1 µg/ml 
propidium iodide (PI; BD Biosciences) for viability. Analysis was performed using a BD 
FACSCalibur flow cytometer. Only the cells negative for PI staining (viable cells) were selected 
for the ADAM12 analysis. 
Cell Surface Biotinylation and Western Blotting 
Cells were washed with DPBS, incubated for 60 min at 4°C with 2.5 mM EZ-link NHS-
PEG12-biotin (Thermo Scientific), and then washed with ice-cold 100 mM glycine/DPBS. 
Cellular proteins were extracted with extraction buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 
1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM 4-(2-aminoethyl)-benzene-
sulfonylfluoride hydrochloride (AEBSF), 5 µg/ml aprotinin, 5 µg/ml leupeptin, 5 µg/ml pepstatin 
A, 10 mM 1,10-phenanthroline; 0.5 ml buffer/well in a 6-well plate). Cell extracts were 
centrifuged at 21,000×g for 15 min at 4°C, and supernatants were incubated for 1 h at 4°C with 
NeutrAvidin sepharose (GE Healthcare; 0.5 ml cell extract/25 µl of resin). The resin was washed 
three times with extraction buffer, eluted with SDS sample buffer; samples were then resolved 
by SDS-PAGE and transferred to a nitrocellulose membrane. Western blotting was performed 
using anti-ADAM12 polyclonal (1∶20,000 dilution), anti-DLL1 (1∶1,000), anti-EGFR 
(1∶5,000 dilution), anti-pY1173 EGFR (1∶5,000) primary antibodies and HRP-conjugated 
secondary antibodies, as described (Li et al., 2012). Signal detection was performed using 
WestPico chemiluminescence detection kit (Pierce). 
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Endo H Treatment 
Stably transduced cells were treated with extraction buffer and centrifuged at 21,000×g 
for 15 min at 4°C. Supernatants were treated with EndoHf denaturing buffer (New England 
BioLabs), boiled, and then treated with Endo Hf (3,000 U), according to the manufacturer’s 
instructions. 
Determination of Cell Doubling Times 
Stably transduced cells were seeded in 6-well plates at the density of 60,000 cells/well. 
After 24, 48, and 72 h, cells were detached and counted with Cellometer AutoT4 (Nexcelom 
Bioscience), in duplicates. Exponential growth curves were fitted to each dataset and the 
doubling times were calculated using a nonlinear regression function in the GraphPad Prism 5.0 
software. 
Evaluation of ADAM12-L-mediated Shedding of EGFR Ligands 
MCF10A cells stably overexpressing WT or mutant ADAM12-L proteins, or cells stably 
transduced with empty pBABEpuro vector, were incubated for 16 h in serum-free media. 
Conditioned media were then collected, pre-cleared by centrifugation, and added to the duplicate 
wells containing “reporter” empty vector-transduced MCF10A cells that were pre-incubated for 
16 h in serum-free medium. After 30 min, cells were washed with DPBS, treated with extraction 
buffer containing phosphatase inhibitors 50 mM NaF, 2 mM Na3VO4, and 10 mM Na4P2O7, and 
analyzed by SDS-PAGE and Western blotting using anti-phospho-EGFR (pY1173) and anti-
EGFR antibodies. 
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Cell Migration Assay 
MCF10A cells with stable overexpression of WT or mutant ADAM12-L proteins, or 
control empty vector-transduced cells, were suspended in MCF10A medium containing 0.1% 
BSA instead of horse serum, and seeded in the upper chambers of Transwell inserts with a 8-µm 
pore size polyethylene terephthalate membrane (BD Biosciences), at 2.5×104 cells/chamber. The 
lower chambers contained the full culture medium supplemented with 5% horse serum and 20 
ng/ml EGF. After incubation at 37°C for 18 h, cells were fixed with 3% glutaraldehyde in DPBS 
for 20 min, washed twice with DPBS, and stained with 0.5% crystal violet in 20% methanol for 
10 min. Cells at the upper face of the membrane were removed with cotton swabs, and cells at 
the lower face were examined with an inverted microscope using a 10× magnification, and 
photographed. Numbers of cells in five random fields were counted, and the mean number of 
migrated cells for each insert was determined. 
ADAM12-L Structure Prediction 
The I-TASSER software (http://zhanglab.ccmb.med.umich.edu/I-TASSER/) (Roy et al., 
2010; Zhang, 2008) was used to predict the structure of the extracellular domain of the mature 
form of human ADAM12-L (amino acids 208-708). The ADAM22 template (PDB: 3G5C) was 
excluded from the I-TASSER template library due to a compact packing of the metalloproteinase 
domain against the cysteine-rich domain and steric hindrance of the pseudo-catalytic site (Liu et 
al., 2009), a feature that may be characteristic for catalytically inactive ADAMs. 
Statistical Analysis 
Fisher’s exact test, unpaired t test, and linear regression were performed using GraphPad 
Prism 5.0. 
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 Results 
The five breast cancer-associated mutations mapping to the extracellular portion of 
ADAM12-L are located in different domains and spread over a region spanning more than 300 
amino acids (Figure 4.1A). We asked whether these mutations might be clustered in a particular 
region in the three-dimensional structure of the protein. Since the X-ray structure of human 
ADAM12-L is not available, we used the I-TASSER protein structure prediction tool (Roy et al., 
2010; Zhang, 2008) to build a 3D model of the extracellular domain of the active form of human 
ADAM12-L comprising the metalloproteinase, disintegrin, cysteine-rich, and EGF-like domains. 
From the model, it is apparent that the cancer-associated mutations are scattered over the entire 
structure and they do not cluster in a particular region of the protein (Figure 4.1 B). 
The three recently identified mutations - T596A, G668A, and R612Q - involve amino 
acid residues in ADAM12 that are highly conserved between species (Figure 4.1C). The G668 
residue is also conserved between human ADAM12 and the most closely related human 
ADAMs, namely ADAM19, ADAM33, and ADAM15 (Edward et al., 2008). In contrast, the 
T596 and R612 residues are not conserved between ADAM12-L and the other three ADAMs 
(Figure 4.1D). To study the effects of the T596A, G668A, and R612Q mutations on the 
functionality of ADAM12-L, we stably expressed WT and mutated ADAM12-L proteins in 
human MCF10A mammary epithelial cells. Western blotting of total cell lysates with an 
antibody specific for the cytoplasmic tail of ADAM12-L demonstrated that the proteolytic 
processing of WT ADAM12-L and the T596A and R612Q mutants was virtually 
indistinguishable (Figure 4.2A). In all three cases, the mature, processed form of ∼90-kDa was 
easily detected, and its abundance was similar to that of the nascent, full-length form of ∼120-
kDa. In contrast, processing of the G668A mutant was significantly inhibited. Staining of live 
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cells with an antibody recognizing the extracellular domain of ADAM12-L and analysis by flow 
cytometry demonstrated that WT ADAM12-L and the T596A and R612Q mutants were readily 
detected at the cell surface, whereas the G668A mutant showed much weaker cell surface 
staining (Figure 4.2B). To further explore the intracellular localization of WT ADAM12-L and 
the mutants, we performed immunofluorescence staining of permeabilized cells with anti-
ADAM12 and anti-KDEL antibody, a marker of the ER. We observed that substantial amounts 
of WT ADAM12-L and the T596A and R612Q mutants were present in post-ER compartments 
located at the cell periphery (Figure 4.2C), consistent with cell surface localization of these 
proteins detected by flow cytometry. In contrast, anti-ADAM12 staining in G668A-expressing 
cells largely coincided with anti-KDEL staining (Figure 4.2C), suggesting that this mutant was 
retained, at least partially, in the ER and explaining why it was poorly detected at the cell surface 
(Figure 4.2B). 
The pronounced effect of the G668A mutation on the processing and localization of 
ADAM12-L is unexpected, given the very conservative nature of the Gly-to-Ala substitution. 
Thus, the maturation of the G668A mutant in the secretory pathway was further probed with 
endoglycosidase H (Endo H) and compared to the WT ADAM12-L. When the lysate of WT-
expressing cells was treated with Endo H, the mobility of the nascent ADAM12-L increased, 
while the mature form was more resistant to the Endo H treatment (Figure 4.3A). This result 
indicated that the mature form, but not the nascent form, progressed through the Golgi 
compartment, where the resistance of N-linked oligosaccharides to Endo H is acquired. The 
G668A mutant, represented predominantly by the full-length form, was sensitive to Endo H, 
further suggesting that this mutant did not efficiently progress beyond the ER. Finally, we 
performed cell surface biotinylation of intact cells expressing the WT or G668A mutant protein. 
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In WT ADAM12-L-expressing cells, the mature form was efficiently biotinylated, whereas the 
nascent form was resistant to the modification (Figure 4.3B). This result indicated that at the cell 
surface of WT ADAM12-L-expressing cells, the mature ADAM12-L form was much more 
abundant than the nascent form. In G668A mutant-expressing cells, the extent of cell surface 
biotinylation of ADAM12-L was considerably lower than in WT ADAM12-expressing cells, 
further indicating that the G668A mutation impaired trafficking of the ADAM12-L protein to the 
cell surface. 
The next question might be: Why is the G668A mutant inefficiently trafficked to the cell 
surface and predominantly retained in the ER? We reasoned that this mutant might be misfolded 
and retained by the protein quality control system operating in the ER. However, using co-
immunoprecipitation, we did not detect interaction between the G668A mutant (or WT 
ADAM12-L) with ER chaperones BiP, Grp94, and calnexin, or with ER stress proteins that 
assist in proper disulfide formation ERp44, ERp57, ERp72, Ero1, PDI (results not shown). Also, 
cellular levels of these chaperones/stress proteins were not elevated in G668A-expressing cells. 
Cycloheximide chase experiments further demonstrated that the G668A mutant was in fact more 
stable than the WT ADAM12-L protein. Estimated half-life of the G668A mutant was 5.9 h, 
which was significantly larger than the half-life of WT ADAM12-L (3.3 h, Figure 4.3C). 
Collectively, these results suggested that although the G668A mutant was retained in the ER, 
most likely it was not misfolded and it was not subject to rapid degradation. 
Next, we asked about the catalytic activity of ADAM12-L mutants. While a mutation 
causing impaired intracellular trafficking of ADAM12-L is naturally expected to cause a 
decrease in the enzyme activity at the cell surface (unless it exerts an indirect effect, such as 
enhancing cell surface expression of a different proteolytic enzyme), a mutation that does not 
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affect intracellular trafficking and processing can still have an impact on the catalysis or 
substrate recognition. For comparison, we also included the D301H and G479E mutants in the 
current analysis. The corresponding D299H and G477E mutations in mouse ADAM12 were 
shown previously to block the intracellular trafficking and processing of the protein, as well as 
ADAM12-mediated cleavage of the substrate protein DLL1 (Dyczynska et al., 2012). 
Trafficking, processing, and catalytic activities of human D301H or G479E mutants have not 
been examined before. The L792F mutation in the cytoplasmic tail of human ADAM12-L was 
reported to have no effect on ADAM12-L trafficking, processing, or catalytic activity 
(Dyczynska et al., 2012; Stautz et al., 2012). 
We used three different approaches to evaluate the catalytic activity of the D301H, 
G479E, T596A, R612Q, and G668A mutants at the surface of MCF10A cells (Figure 4.4A). In 
the first approach, cells with stable overexpression of WT or mutant ADAM12-L were 
transfected with a plasmid encoding DLL1. The full-length (FL) DLL1 and the C-terminal 
fragment (CTF) generated by the proteolytic cleavage were detected by Western blotting, as 
described previously (Dyczynska et al., 2012; Dyczynska et al., 2007). We observed that the 
CTF/FL ratio of DLL1 was higher in cells expressing WT ADAM12-L or the R612Q mutant 
than in control cells, indicative of the catalytic activity of these ADAM12 proteins toward the 
DLL1 substrate (Figure 4.4B). In contrast, the CTF/FL ratio was not increased in D301H, 
G479E, G668A, or T596A mutant-expressing cells compared to control cells, suggesting that 
these four mutations significantly reduced the ability of ADAM12-L to cleave DLL1. 
In the second approach, we focused on ADAM12-L-mediated shedding of EGFR ligands, 
as this function of ADAM12-L has been recently shown to be important in the biology of TNBC 
(Li et al., 2012). Among different EGFR ligands, ADAM12-L was previously shown to cleave 
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EGF (Horiuchi et al., 2007; Fröhlich et al., 2013) and heparin-binding(HB)-EGF (Asakura et al., 
2002; Diaz et al., 2013). Here, the amount of endogenous EGFR ligands shed to the media by 
MCF10A cells stably overexpressing WT or mutant ADAM12-L proteins was evaluated. Cells 
were incubated for 16 h in serum-free media, the conditioned media were then transferred to 
starved “reporter” MCF10A cells, incubated for 30 min, and then the extent of EGFR 
phosphorylation at Tyr1173, one of the major autophosphorylation sites in response to ligand 
binding (Olayioye et al., 2000), was examined. Conditioned media from WT ADAM12-L or 
R612Q mutant-expressing cells increased EGFR phosphorylation in reporter cells (Figure 4.4C). 
In contrast, conditioned media from D301H, G479E, G668A, or T596A mutant-expressing cells 
did not cause elevation in EGFR phosphorylation (Figure 4.4C), suggesting that these mutants 
most likely did not efficiently shed EGFR ligands. 
In the third approach, we investigated the effect of WT and mutant ADAM12-L 
expression on cell migration. We showed previously that overexpression of mouse ADAM12 in 
NIH3T3 cells increased cell migration using scratch wound assay, and that the D299H and 
G477E mouse ADAM12 mutants were inactive (Dyczynska et al., 2008). ADAM12-L has been 
also found to potentiate the migration of head and neck squamous cell carcinoma cells (Rao et 
al., 2012). However, overexpression of ADAM12-L in breast cancer MCF-7 cells did not affect 
cell migration (Roy et al., 2011), and mouse ADAM12 was reported to inhibit keratinocyte 
migration or integrin α4β1-mediated CHO cell migration cells (Harsha et al., 2008; Huang et al., 
2005). Thus, the effect of ADAM12 on cell migration appears to be highly context-dependent 
and may involve distinct mechanisms. In the current study, we used a Transwell assay to assess 
the effect of mutations in human ADAM12-L on the migration of MCF10A cells. While 
overexpression of WT ADAM12-L or the mutants did not affect cell growth (Figure 4.5A), the 
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WT and the R612Q mutant ADAM12-L significantly increased cell migration (Figure 4.5B and 
C). This up-regulation of cell migration required the catalytic activity of ADAM12-L, because 
the E351Q mutant-expressing cells migrated at a rate similar to control cells. Importantly, 
overexpression of the D301H, G479E, G668A, or T596A mutants did not increase cell 
migration, further indicating that these mutants were either not efficiently targeted to the cell 
surface or had activities significantly lower than the WT ADAM12-L and the R612Q mutant. 
A summary of the functional characterization of breast-cancer associated ADAM12-L 
mutations, as well as the properties of breast tumors in which each mutation was identified, is 
provided in Table 4-1. Included in Table 4-1 are also SIFT scores and PolyPhen scores obtained 
from the Ensembl Genome Browser (www.ensembl.org). SIFT is a sequence homology-based 
tool that sorts intolerant from tolerant amino acid substitutions and predicts whether an amino 
acid substitution in a protein will have a phenotypic effect (http://sift.jcvi.org) (Kumar et al., 
2009). PolyPhen-2 is a tool which predicts the variation effect on protein function based on 
physical and comparative considerations (http://genetics.bwh.harvard.edu/pph2) (Adzhubei et al., 
2010). SIFT scores ≤0.05 and PolyPhen scores ≥0.95 designate amino acid substitutions that are 
predicted to be damaging to the structure/function of a protein. As summarized in Table 4-1, 
with the exception of the T596A mutation, there is an agreement between the predicted effect of 
each mutation and the experimentally determined activity of ADAM12-L. Importantly, 
mutations that do not have impact on the ADAM12-L activity - R612Q and L792F - were found 
in TNBCs. Mutations that inhibit the ADAM12-L activity - D301H, G479E, G668A, and T596A 
- occurred in non-TNBCs. Thus, there is an apparent association between the intact activity of 
ADAM12-L and the triple-negative status of tumors, although this association is only borderline 
significant due to the small sample size (P = 0.0667, Fisher’s exact test). 
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 Discussion 
The current study, together with two other previous reports (Dyczynska et al., 2008; 
Stautz et al., 2012), provides an insight into the structural/functional aspects of the currently 
known breast cancer-associated mutations in ADAM12. These mutations are scattered along the 
entire length of the protein, and they do not appear to cluster within a specific region in the three-
dimensional model of ADAM12-L. Among three novel mutations characterized for the first time 
in this study, only one - G668A - has a severe impact on the intracellular trafficking and 
proteolytic processing of the protein. Considering the very conservative nature of the Gly-to-Ala 
substitution, this finding is somewhat unexpected. However, as Gly is highly flexible and can 
adopt conformations that are forbidden for other amino acids, it is possible that the replacing Gly 
with Ala at position 668 is not compatible with the native structure of ADAM12-L. High 
conservation of Gly668 between ADAM12-L and other related ADAMs (Figure 4.1D) further 
suggests the importance of a Gly residue at this position. 
The G668A mutation adds to the other two mutations that were previously found to cause 
ER retention and a lack of proteolytic processing of mouse ADAM12, and are now confirmed to 
inhibit the processing of human ADAM12-L, i.e., D301H and G479E. While we do not find any 
evidence that these mutants are unfolded and rapidly degraded, they must assume a significantly 
different conformation from the WT ADAM12-L to be retained in the ER. Clearly, since these 
three mutants exist mostly as the ∼120-kDa precursors, with the inhibitory pro-domain intact, 
they are expected to be catalytically inactive. The lack of catalytic activity of the D301H, 
G479E, and G668A mutants has been confirmed here by the DLL1 cleavage assay, by the EGFR 
activation assay, and by the Transwell migration assay. 
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The effects of D301H, G479E, and G668A mutations on the structure/function of 
ADAM12-L agree well with the effects predicted by the SIFT and PolyPhen tools (see Table 4-
1). Interestingly, the T596A mutation is predicted to be tolerated by SIFT, but harmful by the 
PolyPhen-2 algorithm. We find that the T596A substitution does not affect intracellular 
processing of ADAM12, and this result is consistent with the fact that with Thr596 is poorly 
conserved between ADAM12-L and other closely related human ADAMs (Figure 4.1D). 
However, we find that the T596A mutation renders ADAM12-L inactive at the cell surface. 
Thr596 is not located at the active site and most likely it is positioned distantly from the 
metalloproteinase domain in the three-dimensional structure of ADAM12 (Figure 4.1B). 
It is currently unclear whether the T596A substitution exerts a long-range inhibitory 
effect on the catalytic site or whether it blocks the interaction of ADAM12-L with its substrates. 
Overall, we conclude that the D301H, G479E, T596A, and G668A mutations should be 
classified as loss-of-function mutations. 
The most striking observation emerging from this study is the apparent association 
between the catalytic activity of ADAM12-L mutants and the type of breast cancer. Two 
mutations that did not have any impact on the catalytic activity of ADAM12-L, R612Q and 
L792F, were found in triple-negative tumors. In contrast, all four loss-of-function mutations, 
D301H, G479E, T596A, and G668A, occurred in non-triple-negative tumors. Thus, it appears 
that loss-of-function mutations in ADAM12-L tend to be excluded from TNBCs. However, a 
larger patient population and possibly a broader mutation spectrum are needed to test whether 
there is indeed a significant association between the type of ADAM12-L mutations and the 
triple-negative status of breast tumors. Interestingly, the ADAM12 gene is located in the genomic 
region that has been recently found to be significantly deleted in Luminal B tumors (cytoband 
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10q26.11, wide peak boundaries chr10:104674916-135534747, q value 0.0056373) (The Cancer 
Genome Atlas Network, 2012). Low q-values associated with gene amplifications/deletions 
(typically below 0.25) suggest that amplifications/deletions at a particular locus are enriched by 
selective pressures (Beroukhim et al., 2010). The same study found that the ADAM12 gene was 
hypermethylated and showed lower expression in Luminal B tumors than in other types of breast 
cancer (Beroukhim et al., 2010). As Luminal B tumors are estrogen receptor-positive (Creighton, 
2012; Beroukhim et al., 2010), these results, together with our functional analysis of ADAM12 
breast cancer-related mutants presented here, collectively suggest that ADAM12 may play 
fundamentally different roles in TNBCs and in non-TNBC. 
We have recently postulated that ADAM12-L may be the primary protease responsible 
for the activation of EGFR in early stage, lymph node-negative TNBCs (Li et al., 2012). This 
conclusion was supported by decreased distant metastasis-free survival times of patients with 
high expression levels of ADAM12-L, increased EGFR phosphorylation in a mouse xenograft 
model of breast cancer, and a strong correlation between the level of anti-ADAM12-L and anti-
phospho-EGFR immunostaining in human breast tumor samples. We have also noticed a positive 
correlation between ADAM12-L and HB-EGF and EGFR in TNBCs, but not in receptor-negative 
non-TNBCs (Li et al., 2012). In estrogen receptor-positive MCF-7 breast cancer cells, 
overexpression of ADAM12-L promoted estrogen-independent proliferation, and this effect of 
ADAM12-L was linked to elevated EGFR activation (Roy & Moses, 2011). Furthermore, a 
recent study demonstrated cancer cells under hypoxia up-regulate ADAM12-L expression, 
leading to increased HB-EGF shedding, EGFR activation, formation of invadopodia, and cancer 
invasion (Diaz et al., 2013). We believe that these results, together with the analysis of breast 
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cancer-associated ADAM12-L mutants described here, point to an important role of ADAM12-L 
in the pathology of triple-negative breast cancer. 
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Figure 4.1 Breast cancer-associated mutations in human ADAM12-L. 
(A) A diagram of human ADAM12-L. Six non-synonymous mutations identified in 
human breast cancers are indicated. S, signal peptide; P, prodomain; M, metalloproteinase 
domain; D, disintegrin domain; C, cysteine-rich domain; E, EGF-like domain; T, transmembrane 
region; Cyt, cytoplasmic tail. (B) Model of the extracellular domain of human ADAM12-L 
generated by the I-TASSER protein structure prediction tool (C-score −0.26, estimated TM 
accuracy of the model 0.68±0.12) (Roy et al., 2010; Zhang, 2008). The metalloproteinase, 
disintegrin, cysteine-rich, and EGF-like domains are shown in purple, blue, yellow, and green, 
respectively. Positions of the five amino acids mutated in breast cancers (red spheres) and the 
side chain of the catalytic residue E351 (cyan sticks) are indicated. (C) Sequence alignment of 
the cysteine-rich and EGF-like domains of ADAM12 from different species. NCBI RefSeq 
numbers are: Homo_sapiens, NP_003465; Mus_musculus, NP_031426; Rattus_norvegicus, 
XP_001054670; Bos_taurus, NP_001001156, Equus_caballus, XP_001490097; Gallus_gallus, 
NP_001136322, and Xenopus_tropicalis, NP_001035103. (D) Sequence alignment of the 
cysteine-rich and EGF-like domains of human ADAM12 and the most closely related human 
ADAMs. NCBI RefSeq numbers are: ADAM19, XP_005266060, ADAM33, NP_079496.1, and 
ADAM15, NP_997080. In C and D, asterisks indicate three novel mutations in human ADAM12 
found in breast tumors (Shah et al., 2012; Jiao et al., 2012). Clustal X color scheme was applied. 
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Figure 4.2 The effect of G668A, T596A, and R612Q mutations on the proteolytic processing 
and intracellular localization of ADAM12-L. 
(A) Proteolytic processing of the WT and mutant forms of human ADAM12-L in 
MCF10A cells. Cells with stable expression of ADAM12-L proteins or control empty vector 
(EV)-transduced cells were selected with puromycin after retroviral infection. Total cell lysates 
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were analyzed by Western blotting using antibody specific for the cytoplasmic tail of ADAM12-
L. Arrowhead indicates the nascent, full-length, catalytically inactive form, and arrow denotes 
the mature, processed, catalytically active form of ADAM12-L. (B) Cell surface localization of 
ADAM12-L was examined by flow cytometry. Live cells were trypsinized and stained with an 
antibody specific for the extracellular domain of ADAM12-L (red) or with isotype control 
antibody (black). (C) Intracellular localization of the WT and mutant ADAM12-L proteins. Cells 
were co-stained with anti-ADAM12 antibody (red), anti-KDEL antibody (endoplasmic reticulum 
marker; green), and DAPI (blue). Control represents cells expressing WT ADAM12-L, incubated 
with pre-immune serum instead of anti-ADAM12 antibody. Arrows indicate ADAM12 staining 
in post-ER compartments. Bar, 20 µm. 
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Figure 4.3 The G668A mutation causes retention of ADAM12-L in the endoplasmic 
reticulum. 
(A) Probing the maturation of ADAM12-L proteins in post-ER compartments by 
treatment with endoglycosidase H (Endo H). Total cell lysates were incubated for 1 h with Endo 
H, followed by Western blotting with anti-ADAM12 antibody. Asterisk indicates the full-length, 
de-glycosylated form of ADAM12-L. (B) Cell surface biotinylation of ADAM12-L proteins. 
Intact cells were incubated for 1 h with membrane-impermeable NHS-PEG12-biotin, followed 
by isolation of biotinylated proteins using NeutrAvidin beads and Western blotting with anti-
ADAM12 antibody. Input (In) refers to total cell lysates prior to Neutravidin binding, and eluate 
(El) refers to biotinylated proteins that bound to the resin. Biotinylation of epidermal growth 
factor receptor (EGFR) served as positive control. (C) Protein stability assay. Cells were 
incubated with 10 µg/ml of cycloheximide for the indicated times, followed by immunoblotting. 
Band intensities of ADAM12-L (nascent and mature forms combined) were quantified by 
densitometry, normalized to β-actin, and analyzed using a single exponential decay model. Half-
lives of the WT and the G668A mutant ADAM12-L were significantly different (3.3 h vs 5.9 h, 
respectively, P = 0.0031). 
 
 138 
 
 
Figure 4.4 Cell-based assays of the catalytic activity of ADAM12-L mutants. 
(A) MCF10A cells with stable overexpression of WT or mutant ADAM12-L proteins, or 
control empty vector (EV)-transduced cells used in assays shown in panels B and C. The E351Q 
mutant is catalytically inactive due to the mutation at the active site and is used as negative 
control. (B) Cells shown in panel A were transiently transfected to express a substrate protein 
Delta-like 1 (DLL1). Cell extracts were subjected to Western blotting with anti-DLL1 antibody. 
The full-length (FL) DLL1 and the C-terminal fragment (CTF) generated by the proteolytic 
cleavage are indicated. Band intensities were quantified by densitometry. The experiment was 
repeated two times, mean values ± SEM are shown. *, P<0.05. Notice that the amount of the C-
terminal fragment (CTF) of DLL1 is increased in WT- and R612Q mutant ADAM12-L-
expressing cells. (C) Cells shown in panel A were serum-starved for 16 h. Conditioned media 
were then transferred to reporter MCF10A cells that were also pre-starved for 16 h, and 
incubation continued for 30 min. The level of phosphorylation of EGFR in reporter cells was 
evaluated by Western blotting using anti-phosho-Y1173 antibody, band intensities were 
quantified by densitometry, and the extent of phosphorylation of EGFR (pEGFR) normalized to 
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the total EGFR protein was evaluated. Conditioned media from EV-transduced cells 
supplemented with 15 ng/ml EGF served as positive control. The experiment was repeated three 
times, mean values ± SEM are shown. *, P<0.05. Notice that EGFR phosphorylation in reporter 
cells was increased upon adding conditioned media from WT- or R612Q mutant ADAM12-L-
expressing cells. 
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Figure 4.5 The effect of WT and mutant ADAM12-L on cell growth and migration. 
(A) Doubling times of MCF10A cells with stable overexpression of WT or mutant 
ADAM12-L proteins, or control empty vector (EV)-transduced cells. The data are shown as 
means with 95% confidence intervals based on 3 independent determinations. (B) Cells were 
analyzed for migration using Transwell assays. Representative images of crystal violet-stained 
cells present at the lower face of the Transwell inserts are shown. (C) Quantification of the 
migration assay. The numbers of migrated cells were counted in five random fields for each 
insert. The data are shown as mean ± SEM from 3 determinations. *, P<0.05.  
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Table 4-1 Summary of breast cancer-associated somatic mutations in ADAM12-L. 
 
 
 
 
  
Mutation 
Molecular 
characteristics 
Sample source Zygosity SIFTa PolyPhenb 
ER 
retention 
Activity 
Reference for ER 
retention/Activity 
D301H non-TNBC Cultured Heterozygous 0 1 ++ − Dyczynska et al., 2008 and this study 
G479E non-TNBC Tumor sample Heterozygous 0 1 +++ − Dyczynska et al., 2008 and this study 
G668A non-TNBC Tumor sample Unknown 0.001 0.998 ++ − This study 
T596A non-TNBC Tumor sample Unknown 0.09 0.999 − − This study 
R612Q TNBC Tumor sample Unknown 0.28 0.89 − + This study 
L792F TNBC Cultured Heterozygous 0.35 0.223 − + Stautz et al., 2012 
	   	   	   	   	   	   	   	   	  a Predicted effect of each mutation on ADAM12-L function according to the SIFT algorithm (Kumar et al., 2009). SIFT scores ≤ 0.05 indicate amino acid 
substitutions that are predicted to be damaging (shown in bold). 
b Predicted effect of each mutation on ADAM12-L function according to the PolyPhen-2 tool (Adzhubei et al., 2010). Scores represent prediction confidence 
that a given mutation changes the protein function; scores ≥ 0.95 are indicated in bold. 
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Chapter 5 - Global discussion 
ADAM12 is a transmembrane protease with multiple biological functions. Studies have 
indicated that ADAM12 expression is dysregulated (Murphy, 2008; Duffy et al., 2009) in 
different types of cancers, including breast cancer, and is often correlated with poor prognosis 
(Cheon et al., 2015; Li et al., 2012; Rao et al., 2012). My dissertation focused on understanding 
the biological functions of ADAM12 in the context of triple-negative breast cancers. I discovered 
that ADAM12 regulates the cancer stem cell-like subpopulations in triple-negative breast 
cancers. I revealed a new mechanism of ADAM12-regulated TGFβ signaling through 
modulation of TGFBR1 mRNA expression in breast cancer cells. I also studied the biochemical 
characteristics of six different somatic mutants of ADAM12 and their impact on ADAM12 
function. 
In Chapter 2, I demonstrated that the loss of ADAM12 not only decreases the percentage 
of cancer stem-like cells (CSCs) in vitro but also significantly compromises the tumor-initiating 
capability of breast cancer cells in vivo, which is the first evidence showing that ADAM12 
regulates the cancer stem-like cell population in triple-negative breast cancers. Cancer stem-like 
cells represent of a small population of cancer cells, having features similar to normal stem cells, 
such as slow cycling and self-renewal (Reya et al., 2001; Al-Hajj et al., 2003). Because of these 
characteristics, cancer stem-like cells are more resistant to chemotherapies and possess the 
capability of initiating tumor formation, which is responsible for tumor relapse and metastasis in 
most types of cancers (Nuti et al., 2014; Pinto et al., 2013). Previously, we found that the level of 
ADAM12 was strongly associated with the decreased metastasis-free survival rate in TNBC and 
that the expression of ADAM12 was significantly up-regulated in TNBC patients with distant 
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metastasis (Li et al., 2012). My findings in Chapter 2 not only support this notion but also 
provide a molecular explanation to the previous observations.  
In addition, I also showed that the exogenous EGF diminishes the reduction of CSC 
subpopulations mediated by ADAM12 knockdown, suggesting that ADAM12 might regulate 
CSC in TNBC through EGFR signaling pathway. Yet we still need direct in vivo or in vitro 
evidences to prove that the activation of EGFR is induced by ADAM12. However, our discovery 
creates an opportunity to fully outline the roles of ADAM12 in breast cancers. Interesting 
questions raised in Chapter 2 are how ADAM12 activates EGFR and which of the downstream 
pathways are modulated by ADAM12 to regulate CSCs. The EGFR pathway is a very complex 
signaling network. Several EGFR downstream cascades have been already reported to regulate 
the stem-like cell phenotype of cancer cells, such as JAK1/STAT3 and Ras/Raf/MEK/ERK (also 
known as MAPK/ERK).  
Extracellular signal-regulated kinase (ERK) is a key player in the downstream EGFR 
signaling pathway and a well-studied CSC regulator in different types of cancers, including 
breast cancer. Studies have shown that the phosphorylation of ERK promotes the transcription of 
genes related with CSC features (Fang et al., 2005; Balko et al., 2013; Ciccarelli et al., 2016). 
Inflammatory cytokine Interleukin-8 (IL8) is one of these genes and it was shown to participate 
in the regulation of breast CSCs (Singh et al., 2013; Singh et al., 2013). Our unpublished data 
shows that the reduced expression of ADAM12 significantly decreased IL8 mRNA levels in 
breast cancer cells. Therefore, it would be interesting to check whether ADAM12 would regulate 
cancer stem like cells by modifying the phosphorylation of ERK proteins. 
PI3K/Akt/mTOR signaling pathway has recently emerged as a potential target for 
inhibiting cancer stem cell activities. The 70-kDa ribosomal protein S6 kinase (p70S6K) is a 
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serine/threonine kinase downstream of PI3K/mTOR and it regulates cell cycle progression and 
cell survival (Heinonen et al., 2008). PI3K/mTOR/p70S6K was reported to induce cancer stem-
like cellular traits in luminal-like breast cancer cells, acute myeloid leukemia, and glioblastoma 
(Corominas-Faja et al., 2013; Altman et al, 2011; Lamour et al., 2015) In addition, p70S6K is 
also involved in the MEK/ERK pathway and is able to be phosphorylated by ERK (Chai et al., 
2015). Studies showed that the attenuation of p70S6K by inhibition of ERK phosphorylation 
impaired the tumorigenic capabilities of glioblastoma, pancreatic, and non-small lung carcinoma 
cells, suggesting that the crosstalk between PI3K/mTOR and MEK/ERK pathways may 
cooperate to maintain the CSC state of cancer cells. (Sunayama et al., 2010; Chai et al., 2015; 
Khan et al., 2012) Coincidentally, the analysis of our RNA-sequencing data suggests that the 
effect of ADAM12 down-regulation on the global gene expression is similar to the gene 
expression pattern induced by the suppression of mTOR signaling. Thus, it is reasonable to 
postulate that ADAM12 may regulate the CSC phenotype in TNBC through modulating the 
phosphorylation of p70S6K by both mTOR and MEK/ERK signaling cascades, or by either of 
the two. In this regard, assessing whether ADAM12 affects the mTOR signaling pathway and the 
phosphorylation of p70S6K is important to elucidate the subsequent processes through which 
ADAM12 regulates the CSC traits in triple-negative breast cancer cells. 
Another important question that needs to be solved is to understand the function of 
ADAM12 at the cell surface during the CSC regulation. As a transmembrane protease, ADAM12 
cleaves several growth factor precursors, including epidermal growth factor receptor ligands 
EGF and HB-EGF (Asakura et al., 2002; Horiuchi et al., 2007). It is likely that the autocrine and 
paracrine EGFR ligands shed by ADAM12 activate EGFR and its downstream signaling 
pathways and thereby maintain the mesenchymal and stem cell state of breast cancer. However, 
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based on the data in Chapter 2, we could not exclude the possibility that ADAM12 may activate 
EGFR and its downstream pathways though protein-protein interactions. The cytoplasmic tail of 
ADAM12 contains cysteine-rich region, which is capable of interacting with Src Homolog 3 
(SH3) domain containing proteins (Stautz et al., 2010). Moreover, another study showed that 
ADAM12 enhanced PI3K/Akt signaling via the interactions with integrin-linked kinase (ILK), 
which did not require the metalloprotease activity of ADAM12 (Leyme et al., 2012). To address 
this question, an ADAM12 specific inhibitor or antibody could be applied to block the protease 
activity and then to test whether ADAM12 is still capable of regulating the cancer stem-like cell 
populations.  
In Chapter 3, I described a new mechanism by which ADAM12 modulates the strenght of 
TGFβ signaling via the regulation of TGFBR1 mRNA levels, which is the first study reporting a 
role of ADAM12 in the regulation of TGFβ signaling at the endogenous ADAM12 expression 
level. An important question that emerged from this study is: how would ADAM12, a 
membrane-located protease, regulate the transcription of TGFBR1 inside the nucleus? What 
would be the communicating pathway that connects ADAM12 with the transcription machinery 
of TGFBR1? An interesting observation of my study is that ADAM12 regulates TGFBR1 mRNA 
independently of TGFβ signaling. Though little is known about the regulation of TGFBR1, a 
recent paper has shown that Notch signaling is involved in the regulation of TGFβR1 at the 
transcriptional level (Abrahams et al., 2015). Coincidentally, our previous work showed that 
ADAM12 cleaves Delta-like l, a ligand activating Notch receptor (Dyczynska et al., 2007). 
Theses evidences together suggest that ADAM12 may mediate the regulation of TGFBR1 
transcription via the Notch pathway. To test this hypothesis, we need to investigate whether 
constitutively active Notch would block the down-regulation of TGFBR1 mRNA induced by the 
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loss of ADAM12. In another approach, we could use bioinformatics analyses. With the 
availability of ChIP datasets, the transcription factors that could potentially bind to the promoter 
region of the TGFBR1 gene can be predicted by computing softwares (such as the Genome 
Browser at UCSC and PROMO at IMIM-UPF). The validation of these predicted candidates 
would further help to pinpoint the upstream signal-transducing routes through which ADAM12 
regulates TGFBR1 mRNA.  
There are also some interesting issues not discussed in Chapter 3 but still worthy of 
investigation; for instance, the protein-protein interaction between ADAM12 and TGFβR1 at cell 
surface or in other cellular compartments. It is possible that ADAM12 may increase TGFβR1 
protein stability and thereby enhance the intensity of TGFβ signaling. Another question is 
whether the role of ADAM12 in TGFβ signaling is universal in all types of breast cancers or 
whether this observation is only limited to breast cancers of certain molecular characteristics. 
TGFβ signaling is important for breast cancer cells to maintain the mesenchymal state and to 
acquire the resistance to chemotherapies (Ikushima et al., 2009; Bhola et al., 2013). I believe that 
an in-depth analysis of ADAM12 function in TGFβ signaling will not only increase our 
knowledge of ADAM12 in the pathology of breast cancer but, more importantly, it will lay a 
solid foundation for the development of ADAM12 targeting therapies in the future. 
In Chapter 4, I identified the biochemical characteristics and the biological outcomes of 
six different somatic mutations in the ADAM12 gene in human breast cancers. My data indicates 
that the correct proteolytical processing is critical for the surface localization and proper function 
of ADAM12. Importantly, ADAM12 harboring D301H, G479E, G668A, and T596A mutations 
and showing impaired protease activity do not appear in breast cancers with the triple-negative 
status. This observation reveals an apparent relationship between the intact activity of ADAM12 
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and the triple-negative subtype of breast cancer, though the correlation appears border-line 
significant (P =0.0667, Fisher’s exact test) due to the small sample size (n = 6). This finding 
again supports the notion that ADAM12 with active metalloprotease function might be required 
for the progression of triple-negative breast cancers. 
To summarize, all these results indicate that ADAM12 may be a potential therapeutic 
target in triple-negative breast cancer. Specific antibodies targeting the protease domain of 
ADAM12 or a recombinant protein mimic the pro-domain of ADAM12 (Miller et al., 2015) 
would be a good targeting strategy, when the protease activity of ADAM12 is required for the 
tumor development in breast cancer patients. In contrast, the protease inhibition method may not 
be needed if the function of ADAM12 is mediated via the interaction of its cytoplasmic domain 
with other molecules. In such a case, ADAM12 targeting antibody could be potentially 
conjugated with certain cytoplastic chemicals or ADAM12 targeting siRNAs. The thorough 
understanding of the roles of ADAM12 in breast cancers will empower us to design ADAM12-
targeting therapies, with much more efficient and precise outcomes. 
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